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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 The relevance of an arthritis model in the rhesus monkey 
The autoimmune rheumatic diseases, from which RA is probably the best known, 
comprise a group of chronic disorders forming one of the most challenging 
problems of modem medical research. In spite of considerable research, the etiology 
of RA and other human arthritic diseases remains obscure creating a great obstacle 
for developing specific therapies. 
During the last years several observations provided more insight in the 
pathogenic mechanisms involved in human chronic arthritis. A fundamental 
discovery was the association existing between the susceptibility to develop 
particular rheumatic diseases and certain genes localized within the MHC (1-3). The 
human MHC, designed HLA, encodes several classes of polymorphic gene 
products. Among them are the class I (HLA-A, -B and -C) and class II (HLA-DR, 
-DQ and -DP) region products. An allele encoded by the HLA-DR region, named 
HLA-DR4, seems to be associated with a progressive form of severe RA (4). It is 
not clear yet where such type of associations are based on, but it is known that MHC 
class I and II molecules are membrane bound glycoproteins which can bind and 
present (self) peptides to (autoreactive) Τ lymphocytes. The polymorphism of class I 
and class II molecules is not randomly located but amino acid sequence variability 
is concentrated at positions involved in the interaction with either epitopes of the 
antigen and/or the TCR (5, 6). Therefore, the MHC plays a pivotal role in 
controlling the immune response. 
The involvement of Τ cells in RA is a second important feature of the disease, 
although their exact influence is still under discussion (7). The potential role of 
autoreactive Τ helper lymphocytes is substantiated by immunohistological studies of 
RA synovium, where perivascular aggregates of CD4+ Τ cells, closely situated next 
to APC, can be demonstrated (8, 9). In addition, the role of Τ cells in RA is 
supported by the finding that partial elimination or inhibition of the function of 
these cells, by a variety of techniques, leads in some patients to remission of the 
disease (10). Furthermore, evidence for involvement of specified subsets of Τ cell 
are suggested by observations of Τ cell oligoclonality in affected joints of RA 
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patients (11, 12), although these data are debated (13). 
A last crucial RA related finding is the fact that RA can be classified among the 
so called immune complex diseases because of the presence of autoantibodies and 
immunocomplexes in synovial fluid, tissue and sera (14). 
So, the conclusion can be drawn that in the pathogenesis of RA the allelic variation 
of the MHC genes, together with a certain autoreactive Τ and В cell repertoire, 
constitutes important factors which may influence susceptibility (or resistance) to 
the disease. 
Autoimmune diseases can be regarded as the clinical result of a disregulated 
immune system that has lost its immunologic tolerance to an autoantigen. 
Immunologic tolerance to an autoantigen may be achieved by deletion or 
inactivation of autoreactive Τ cells during their differentiation in the thymus (15, 
16). To understand autoimmunity it is important to know how autoreactive Τ cells 
escape thymic depletion and which factors control how these autoreactive Τ cells 
(and also autoreactive В cells) become or remain activated. 
Animal models are indispensable in studying factors governing maintenance or 
breaking of self tolerance and the components which subsequently regulate the 
development to a clinical manifested autoimmune disease. Rodent models have 
proven to be valuable, since they have given information about the autoantigens 
involved, associations with the MHC and regulatory mechanisms behind 
autoimmunity (17). However, most information is based on observations performed 
in a limited number of inbred strains. 
Profound differences between the immune systems of rodents and man have 
been described. One of the consequences is that extrapolation of experimental data 
from rodent studies to man has to be done with caution. In this respect nonhuman 
primates may provide a more reliable system and can play an important role. 
Extrapolation of data obtained in nonhuman primates to man might be more relevant 
because of their close phylogenetic relationship and because they share many 
biologic and immunologic similarities. 
The knowledge of the MHC systems in different nonhuman primate species has 
rapidly expanded (18, 19). On basis of these data it has been shown that some 
alleles of different, but related, species are more similar to each other than the MHC 
alleles within a species (20). This high degree of shared MHC similarity, observed 
between different primate species, has also functional significance as reflected by 
successful antigen presentation across a species barrier (21). The current knowledge 
of the MHC of the rhesus monkey (Macaca mulatta), named MhcMamu (22) and 
located on chromosome 2, is for a great deal based on serologic information (23, 
12 
24). In this way 27 different class I molecules (13 A loci, 14 В loci) could be 
identified as well as 10 different Mamu-DR molecules. Recently, restriction 
fragment length polymorphism analysis has shown that most of the serologically 
defined DR specificities can be divided into subtypes (25). 
The close phylogenetic relationship between rhesus monkeys and man is also 
reflected by the high structural conservation of many surface structures which can 
be found on several types of PBMC (26-28). Many of these surface molecules have 
important functions in the immune response (29). In addition, Ahmed-Ansari et al. 
(30) has shown that certain rhesus monkey Τ cell subtypes, phenotyped with 
specified anti-human MoAb, have similar immunologic functions as their human 
counterparts. 
Similarities beween the immune systems of man and rhesus monkey make a 
rhesus monkey arthritis model suitable to test the efficacy and safety of a new 
generation of immunomodulating / anti-rheumatic agents. Especially biological 
response modifiers with an exclusive biological activity in primates might be 
suitable candidates. Most biological response modifiers have multiple biological 
effects, so results obtained in vitro cannot be directly extrapolated to the therapeutic 
efficacy in humans. This point again stresses that monkey studies can be an essential 
prerequisite for the successful application of drugs in man. Examples of biological 
response modifiers, which already have been applied in monkeys, are human 
interferon preparations (31) and human-specific MoAb directed to several surface 
molecules (32-34). 
The disadvantages of the monkey model are ethical and technical. Also the 
relatively high costs of experiments with rhesus monkeys prevent the use of large 
numbers of animals. Nevertheless, rhesus monkeys have been used, and in some 
areas with increasing frequency, as animal models for human infectious diseases 
(35), nowadays especially in the case of acquired immunodeficiency sydrome 
(AIDS) (36), bone marrow- (37), heart- and kidney transplantation (38) and 
autoimmunity (39). 
In all these studies the most important reason for using rhesus monkeys was that the 
collected experimental data can be extrapolated to the clinical situation with more 
confidence than data obtained in rodent models. 
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1.2 Spontaneous arthritic manifestations in nonhuman primates 
Nonhuman primates are our closest living relatives. As in the human population, 
spontaneous manifestations of arthritis, although described by only a few papers, do 
occur in these animals. 
One report describes spontaneous AS in two old rhesus monkeys (> 18 year old) 
and the manifestation of hyperosteotic AS in one rhesus monkey (40). Benditt & 
Eriksen (41) have described three rhesus monkeys with inflammatory activity of the 
joints resembling RA involving knee joints and the proximal IP joints. All monkeys 
had amyloidosis, the extracellular deposition of amyloid fibrils in many organs. 
Also other studies reported the occurrence of amyloidosis in association with 
chronic arthritis in respectively the rhesus monkey (42) and baboon (43). 
Concerning the etiology of arthritis in nonhuman primates a role of certain 
pathogens has been suggested. In 5 rhesus monkeys with chronic arthritis three 
showed an ulcerative enterocolitis associated with Shigella flexnerii (44). Moreover, 
four had rheumatoid factor present and four also amyloidosis. The description given 
of the knee joints, both gross and microscopic, resembled known manifestations of 
RA. Another case was provided by a young male gorilla that developed sponta-
neously systemic and articular manifestations similar to RA (45). This arthritic 
activity however, was likely associated with a mycobacterial infection and was 
successfully treated with the antibiotic tetracycline. 
A more elaborate study in 152 rhesus monkeys showed in the joints of only 1 
animal histological changes which resembled closely those found in human RA 
(46). 
In conclusion, signs of spontaneous (especially RA like) arthritis can be found in 
monkeys, but more study will be necessary to obtain detailed insight in the 
incidence and forms of arthritis in these animals. 
1.3 Experimentally induced arthritis in nonhuman primate species 
Only a few publications have described the attempts to elicite experimentally 
arthritis in monkeys. To demonstrate whether cells, present in synovial fluid or 
synovial membrane of RA patients, are involved in the etiology of RA, twenty-five 
baboons were injected intravenously and intra-articularly with these cells. No signs 
of arthritis were recognized during 3 years of observation (47). A study with 
marmosets {Callithrix jacchus) showed that intra-articular injection of a mixture of 
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methylated-BSA plus Bordetella pertussis results in chronic synovitis (48). 
The first case of experimental induced arthritis in monkeys, which was induced 
by extra-articular immunization, appeared in the literature in 1986. It was shown 
that six female squirrel monkeys (Saimirí sciureus) immunized with native B-СП in 
CFA developed arthritis 3 to 6 weeks later (49). This CIA was symmetrical and 
involved mainly the IP and MCP joints. Although three monkeys suffered from an 
extremely bad condition and died, the other three showed a spontaneously remission 
of their arthritis. All monkeys developed antibody titers to native B-CH, as was 
measured by the passive hemagglutination technique. In the same study three male 
cebus monkeys (Cebus albifrons), also sensitized with B-CII in CFA, did not 
develop arthritis and these animals had a significantly weaker antibody response to 
B-CII as compared to the (CIA susceptible) squirrel monkeys (49). The relation 
between the capability to produce a high titer of anti-CII antibodies and the 
development of CIA seemed also present in cynomolgus monkeys (Macaca fasci-
cularis) (50). In cynomolgus monkeys the capability to produce anti-CII antibodies 
was clearly sex-linked; only females developed arthritis together with a high titer of 
antibodies to autologous СП (50). 
The induction of CIA in rhesus monkeys, by immunization with native B-CII in 
CFA, has also been reported (51-53). In all studies rhesus monkeys were immunized 
systemically, but the way of immunization differed. Yoo and coworkers (51) 
induced CIA in all immunized female rhesus monkeys by injecting the animals i.m. 
in the posterior thigh with 2.0 mg native B-CII in CFA followed by 2 booster 
immunizations of 1.0 mg B-CII in ICFA. In contrast to cynomolgus monkeys, 
susceptibility to CIA in rhesus monkeys seems not sex-linked because Rubin et al. 
(53) showed that all 7 male rhesus monkeys, upon several i.d. immunizations with 
1.0 mg B-CII, developed arthritis. CIA could also be induced in rhesus monkeys by 
implantation of nitrocellulose filters coated with B-CII in the peritoneal cavity (54). 
Thus, the use of CFA as adjuvant is not crucial for the induction of CIA in rhesus 
monkeys. This may be important because it has been reported that CFA itself has 
arthritogenic capacities in rats (55). As expected, CFA elicits a more severe arthritis 
in rhesus monkeys while immunization with the СИ coated nitrocellulose filters 
results only in a sub-clinical arthritis (54). This might be explained by the fact that 
nitrocellulose functions only as a slow release device of the antigen, but not as 
adjuvant. 
Till now, СИ is the only described arthritogenic antigen which after extra­
articular immunization induces arthritis in nonhuman primates. The resistance of the 
cebus monkey and the clear sex-linked susceptibility in the cynomolgus monkey 
15 
raises questions whether susceptibility versus resistance to CIA in nonhuman 
primates is genetically controlled. 
1.4 Type II collagen 
In general, collagen molecules are characterized by their organization in triple-
helical fibrils containing peptides with repeating glycine-X-Y triplets and the 
presence of hydroxyproline and hydroxylysine (56). At present, at least 13 types of 
collagen differing in amino acid composition have been identified. Most of these 
collagens have a structural function in the extracellular matrix of connective tissues. 
СП is the main protein of cartilage and can also be found in a few other tissues 
such as the vitreous body of the eye. СП can be isolated from cartilage by limited 
pepsin-digestion followed by a series of precipitations from solutions of varying pH 
and ionic strengths (57). The most striking feature of СП is its high content of 
hydroxylysine and glycosidically bound carbohydrate. СП is synthesized by 
chondrocytes as a procollagen molecule with non-collagenous amino- and carboxy 
peptides. These peptides are removed by extracellular processing and subsequently 
the molecules are organized into fibrils; fine fibrils around the chondrocytes and 
thicker ones distributed elsewhere in the cartilage (58). The СП fibrils form a 
network which contains proteoglycans, the molecules which together with enclosed 
tissue fluid give articular cartilage its specific elasticity and resistance to com­
pression (59). 
CII is a molecule which, upon i.d. immunization in different experimental 
animals, elicits an autoimmune mediated arthritis (see Chapters 1.3 and 1.6). From 
an immunologic point of view it is important that certain immunogenic epitopes of 
СП are exposed at the surface of intact cartilage (60) and because no basal 
membrane or other barrier in the synovium prevents proteins from entering the 
synovial fluid (61), cartilage may be a target for binding of anti-CII antibodies. 
1.5 Type II collagen immunity in humans 
Two prominent questions arising in the study of human arthritis are 1) whether 
autoimmune reactions to cartilage components occur and 2) to which extend such 
reactions contribute to the initiation or perpetuation of the inflammatory process in 
the joint. In this respect many studies are performed to investigate autoimmunity to 
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СП in humans. 
Little is known about CII-reactive Τ cells in humans. The most direct evidence 
for the presence of CII-reactive Τ cells in healthy individuals was recently provided 
by Lacour et al. (62). In human arthritis, there are indications that Τ cells, 
proliferating upon in vitro exposure to СП, accumulate in joints of RA patients 
(63,64). 
Concerning antibodies directed to СП, elevated serum levels were measured in 
patients with bilateral progressive sensorineural hearing loss (65) and in a variety of 
rheumatic diseases like RA (66, 67) relapsing polychondritis (68) and AS (69). 
Deposition of СП reactive antibodies have been observed in synovial tissue (70), 
synovial fluid (71) or cartilage (72) of some patients with RA. The assumption that 
СП reactive antibodies may play a role during early stages of RA is based on longi­
tudinal studies indicating that these antibodies could be measured preferentially in 
patients with early symptoms of RA (73) and were absent in pre-illness sera (74). 
The specificity of the anti-CII antibody response in RA has been investigated in 
further detail because it is assumed that antibodies directed to conformational 
epitopes, which can be found on intact, native СП are involved in the initiation of 
the disease (60). On the other hand, the presence of antibodies directed to non-
conformational epitopes, present in the primary structures of СП, suggest that 
denatured СП (i.e. CII-fragments eroded from the cartilage surface, for instance due 
to the inflammatory process) may function as autoantigen involved in perpetuation 
of joint inflammation. But this differentiation in the humoral immune response to 
СП is difficult to establish, because most studies reported the presence of antibodies 
directed to both conformational- and linear structures of CH in different stages of 
RA (75,76). 
Studies involved in mapping of the B-cell epitopes on СП suggest that there are 
several immunogenic epitopes. The humoral immune response is directed to 
different parts on the molecule, both containing common (species non-specific) 
epitopes as well as species-specific epitopes (72, 76, 77). It is reported by some 
investigators that the production of anti-CII antibodies in RA patients may be under 
the genetic control of the HLA-DR1 and -DR4 immune response gene products 
(78,79), but these findings are contradicted by data from others (80, 81). 
It is far from clear yet whether anti-CII antibodies are involved in the 
pathogenesis of RA, but there is strong evidence for their arthritogenic capacities 
because purified anti-CII serum antibodies from a RA patient were found to induce 
arthritis in naive mice (82). 
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1.6 Type II collagen induced arthritis in rodents 
While animals like guinea pigs are insensitive to CIA (83), polyarthritis can be 
induced in certain strains of rats and mice by i.d. injection of native heterologous or 
homologous СП (84-87). CIA induced by heterologous СП (mainly from bovine or 
chicken origin) is a monophasic disease, whereas immunization with homologous 
СП usually results in a perpetuating arthritis (88). 
The arthritic activity is usually most severe in the ankle joints, but also the knee 
joints can be affected (86,89). The very early histopathology of the affected joint in 
CIA shows an infiltration of CD4+ Τ cells and a proliferation of synovial lining 
cells, with an increased expression of MHC class II antigens (90-93). Also MHC 
class II- and Fc-receptor expressing macrophages and relatively few В cells and 
plasma cells can be found in the hyperplastic synovial lining layer (93). Subsequent 
development of arthritis can be divided into two stages. First a massive infiltration 
of PBMC and severe oedema of synovium and extra-articular tissue. During the 
second stage, a pannus tissue is formed with activated macrophages and Τ cells and 
a few dendritic cells and fibroblasts (94). It appeared that macrophages are 
important effector cells in the joint destruction and that activated Τ cells as well as 
immune complexes are involved in the induction of the macrophage proliferation 
and activation (91). 
Generally it is considered that the histopatology of the established inflamed joint 
in CIA resembles that of the chronic proliferative synovitis characteristic of human 
RA (84,88,95-97). Both in CIA and RA prostaglandin E2 and proteases, such as 
collagenase contribute to the destruction of cartilage (98,99), as well as the activity 
of neutrophils and reactive oxygen species (100-102). Considerable evidence 
indicates that CIA is initiated by an immune response to СП that is regulated both in 
rats and mice by the MHC (96,103,104). More precisely, in rats the responsiveness 
to B-СП and the development of arthritis is linked to the RTIu MHC locus (105). In 
mice, the linkage has been mapped to the class II region (103). Holmdahl et al. 
(106) have shown that only strains expressing I-Aq or I-Ar (or closely linked) 
molecules developed arthritis, accompanied by a humoral response to mouse-CII, 
upon immunization with heterologous- or mouse-CII. Comparison of the I-A-beta 
first domain exons of the susceptible H-2q mice with the H-2p mice (CIA-resistant) 
resulted in the identification of a site on the I-A-beta chain that is involved in 
susceptibility for CIA (107). Analysis of the nucleotide sequences coding for the 
first domains (this region may be important in antigen presentation) of the I-Aq and 
I-Ar molecules revealed high similarities (108,109). 
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The association beween МНС and CIA, together with the necessity to immunize 
with, for antibodies important, conformationally intact ("native") collagen to induce 
CIA, suggest that both В and Τ cells mediate anti-CII immunity and are both crucial 
for development of CIA (110). The importance of antibodies in the induction of CIA 
has been demonstrated by the observation that anti-CII enriched immunoglobulin 
fractions, obtained from arthritic rats and mice, as well as anti-CII MoAb can induce 
arthritis when transferred to healthy animals (111-113) or nude rats (114). In 
contrast to the arthritis induced by immunization with СП, the arthritis induced in 
these transfer experiments is not restricted to certain MHC haplotypes and has a 
transient character without destructive lesions in the joint (115). The involvement of 
anti-CII antibodies in CIA is also supported by the observation that complement 
plays a crucial role in the initiation of CIA (116-118). Moreover, the disease can be 
inhibited by pretreatment with anti-IgM antibodies (119) or applying anti-idiotypic 
MoAb's directed to an idiotope on anti-CII antibodies (120). 
It seemed that В cells producing anti-CII antibodies are easily activated after the 
primary immunization with СИ (121). The produced antibodies are mainly of the 
IgG2a isotype (122), suggesting the activation of memory В cells. There are 
indications that anti-CII antibodies, which can have rheumatoid factor specificity 
(122, 123) or binding capacities to the activated complement factor Clq (124), 
recognize different epitopes on the СП molecule (125, 126). Untili now 2 major 
immunogenic and arthritogenic В cell epitopes have been localized in the region of 
the СП molecule designated as CB11 (= peptide of 272 amino acids obtained by 
cleavage of СП by cyanogen bromide) (127, 128). 
Evidence supporting the role of Τ cells was obtained from the following 
observations: a) development of disease can be prevented by treating the animals 
with anti-thymocyte serum or with antibodies directed to CD4, the TCR, MHC class 
II molecules or the IL2 receptor (129-133) b) it is impossible to induce CIA in nude 
rats (91) and mice (134) c) arthritis can be induced in normal mice via adoptive 
transfer of СП-specific Τ cell lines (135-138) d) cyclosporin treatment inhibits CIA 
and the anti-CII antibody response (139, 140). Τ cells expressing certain V-beta 
allotypes are thought to play a central role in CIA (141, 142). Whether susceptibility 
to CIA is associated with the usage of particular V-beta elements is yet not certain. 
In vivo experiments showed that depletion of Τ cells expressing V-beta-8 (thought 
to be relevant for the induction of CIA) did not alter CIA (143). Other arguments 
against the central role of certain TCR V-beta allotypes came from studies that 
showed that CIA could be induced in the susceptible DBA/1 mouse but not in the 
SWR mice. Both mice strains are MHC identical and showed a CII-dependent 
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proliferative Τ cell response after immunization with СП (144). This shows that 
both mice strains do not lack anti-CII Τ cells. Even bone marrow transplantation 
from DBA/1 to SWR had no influence on the resistance for CIA in the SWR strain 
(145). The genetic factor(s) responsible for the resistance to CIA in SWR mice are 
unknown. 
Concerning immunoregulation to the autoantigen СП, it is shown in naive 
healthy mice that anti-CII Τ cells exist in the periphery (146), suggesting that a 
regulatory system maintains these autoreactive Τ cells in an anergic stage. The 
existence of such a regulatory system is also indicated by studies in which antigen-
specific hyporesponsiveness to СП and resistance to CIA could be induced by 
pretreating the animals intravenously, orally or intraperitoneally with soluble СП or 
collagen-coupled spleen cells (147-150). Probably, when СП is not administered 
into the skin in its native constitution but when it is administered along another 
route or applied in its denatured form, an (antigen) specific mechanism is installed 
or activated which facilitates resistance to CIA. The nature of such a hypothesized 
mechanism is not known, but there is some evidence that lymphocytes may be 
involved. By in vivo administration studies with MoAb's directed to CD4 + and 
C D 8 + Τ cells Williams et al. (151) showed that both Τ cell subsets govern in 
resistance to CIA; CD4 + cells in an early- and CD8 + cells in a later stage. Other 
studies have shown that lymphocytes are directly involved in suppressing CIA by 
suppressing CII-reactive antibody production (152) and that suppression to CIA can 
be transferred to naive animals with both spleen cells and CD4 + cells isolated from 
CII-immunized animals (137,153-156). 
Concerning СП derived epitopes operating in the immunoregulation of CIA, it is 
likely that next to epitopes involved in the triggering of CIA (127, 128) other 
epitopes are involved in resistance cq. suppression of CIA. Myers et al. (157) 
identified a CII-derived peptide of 25 amino acids which could induce tolerance and 
suppression of disease. The suggestion that Τ cells mediate suppression to CIA is 
also supported by the finding that both cyclophosphamide and cyclosporin treatment 
can abrogate suppression to CIA (158,159). 
1.7 Aim of the study 
The aim of this study was to establish an experimental arthritis model in the rhesus 
monkey (Macaca mulatta), to compare the clinical and pathologic parameters with 
human arthritis and to investigate the association of relevant immunologic para-
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meters with the induced arthritis. 
The study has been performed with a panel of outbred rhesus monkeys of the colony 
of the Institute of Applied Radiobiology and Immunology-TNO (ITRI-TNO), 
Rijswijk, The Netherlands. 
One part of this study comprising an identification of humoral and cellular 
compartments of the immune system which influence the onset and course of the 
experimentally induced arthritis. To this purpose, the antibody repertoire, antigen 
specific Τ cell proliferation and some cytokine profiles were monitored in responder 
and non-responder rhesus monkeys. The Institute contains a primate colony in 
which all animals are characterized for their MhcMamu-A, -B and -DR locus alleles. 
For this reason a second part of this study was focussed on identifying MHC related 
susceptibility or resistance genes associated with experimental induced arthritis. 
This was done by comparing the MHC repertoire of responder and non-responder 
animals. Identification of MHC immune response genes associated with CIA will 
allow the possibility to study their biological role in autoimmunity. 
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SUMMARY 
The induction of experimental arthritis in rhesus monkeys was studied by i.d. 
immunization of B-CII and antigens derived from MT, Streptococcus pyogenes and 
Eubacterium aerofaciens. The tested bacterial antigens proved to be not arthrito­
genic. In this study B-CII induced clinical arthritis in 50% of the rhesus monkeys. 
CIA in rhesus monkeys proved to be a potential model to study clinical, serologic, 
histological, genetic and immunologic features associated with human RA. 
INTRODUCTION 
In recent years, strong evidence has accumulated that human RA is an autoimmune-
mediated arthropathy (1). To understand more about the factors contributing to 
arthritis in susceptible individuals, animal models have been used to investigate the 
pathogenesis of the disease. A widely used model in rats is adjuvant arthritis, 
inducible by immunization with MT (2). There is evidence for a role of Myco­
bacterium in patients with RA. In these patients Τ cell reactivity to MT has been 
reported (3) and patients with advanced cancer, treated with BCG immunotherapy, 
may develop arthritic symptoms (4). Arthritis in rats has been induced by adminis­
tration of cell walls derived from group A streptococci (5) or from Eubacterium 
species (6). In human patients Streptococcal infections occasionally give rise to 
acute rheumatic fever (7). The induction of arthritis by Eubacterium cell wall 
fragments, a major component of the human anaerobic faecal flora, suggests a 
possible etiological role of intestinal bacteria in RA (8). A non-bacterial rodent 
model is represented by CIA. Antibodies to СП are found in sera derived from 
patients with relapsing polychondritis (9) and in some instances for RA (10, 11). 
Thus, the immune response to СП may be an event of general importance in the 
pathogenesis of human RA. All the above mentioned arthritis models in rodents 
share common clinical and histological features with human RA. Nevertheless, the 
relevance of these experimental rodent models for human arthritis is debated (12). 
The study of arthritis in rhesus monkeys is, because of its close phylogenetic 
relationship with man (13) interesting, and may reflect many similar immunologic 
features of the human disease. The natural occurence of arthritis in non-human 
primates has been described in the gorilla (14) and in rhesus monkeys (15, 16, 17). 
It is possible to induce arthritis in rhesus monkeys (18, 19) and squirrel monkeys 
(20) by i.d. injection of B-CII. In this study arthritogenic properties of a number of 
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bacterial antigens and B-CII in the rhesus monkey were investigated. Next to 
clinical observations, rontgenological and histological examinations were 
performed. Moreover, a number of hematological, immunologic and serologic 
parameters was measured. The aim of this study was to compare the clinical 
pathologic and immunologic parameters with those observed in human RA in order 
to examine the relevance of experimentally induced arthritis in the rhesus monkey 
as a model for immune mediated arthritis in man. 
MATERIALS AND METHODS 
Animals 
All rhesus monkeys (Maccaca mulatta) are unrelated and were bom and raised in 
the Rijswijk TNO Primate Center. The female monkeys were 3.0 to 21.0 years of 
age weighing 3.9-5.8 kg. The male monkeys were 4.0 to 21.0 years of age weighing 
4.4-9.3 kg. The animals were examined, weighed and bled under ketamin anesthe­
sia. If an animal was experiencing severe pain it was given twice a day 0.06 mg 
Buprenorfine (Temgesic, Warrick B.V., The Netherlands) by i.m. injection. 
Collagen preparation 
B-CII was prepared from either bovine joint cartilage (kindly donated by Dr. W. van 
der Berg, University of Nijmegen, The Netherlands) or nasal septum cartilage. 
Purification of collagen from both sources was performed in the same manner. The 
cartilage was dissected free of surrounding connective tissue and bone and extracted 
in 4M guanidine chloride for 24h at 4°C. The precipitate, obtained by 
centrifugation, was subjected to a limited pepsin digestion (1 mg/ml) for 48 h in 0.1 
M HAc at 20oC in the presence of gentamicine (1 μΐ/ml). The supernatant was 
collected by centrifugation and adjusted to pH 7.4. Purification of СП was 
performed by salt precipitation with 20% NaCl during 48h at 40C. After centrifu­
gation the precipitate was dissolved into 0.5 M HAc and dialyzed against the same 
solvent during 5h. This solution was centrifugated, the supernatant was collected 
and a second precipitation step was performed with 5% NaCl at 4°C overnight. The 
precipitated collagen was collected by centrifugation and washed with distilled 
water and subsequently stored lyophilized at -20 0 C until use. 
Bacterial antigens 
Heat-killed MT H37Ra was purchased from Difco Laboratories (Detroit, USA). Cell 
33 
wall fragments of Streptococcus pyogenes and Eubacterium aerofaciens were 
prepared as described previously (5). 
Immunization procedures 
All antigens were injected i.d. on the lower back. 
Bacterial antigens (Table 1) Five rhesus monkeys were injected with 10 mg MT 
H37Ra preparation, emulsified in ICFA (Difco, Detroit, USA). 
Four monkeys were injected with an emulsion of Streptococcus pyogenes cell walls 
in ICFA. Two of these monkeys received in total 2.5 mg and two received 5.0 mg. 
All of these four monkeys were challenged at day 105 by immunization with 4.0 mg 
Streptococus pyogenes cell wall fragments emulsified in ICFA. 
Four rhesus monkeys were injected with an emulsion of Eubacterium aerofaciens in 
CFA. Two of these monkeys received 5.0 mg and two received 10.0 mg. 
Collagen (Table 1) For the primary immunization СП, isolated from bovine joint, 
was dissolved in 0.1 M HAc and emulsified in CFA (Difco, Detroit, USA). Six 
rhesus monkeys received 3.0 mg of СП, whereas two others received 1.0 mg СП. 
Four of these were challenged on day 87 with 3.0 mg СП, isolated from bovine 
joint, dissolved in 0.1 M HAc without adjuvant. The other monkeys were challenged 
at day 94 with 3.0 mg СИ isolated out of the nasal septum. This СП was dissolved 
in 0.1 M HAc and emulsified in ICFA. 
Clinical assessment of arthritis 
Monkeys were observed daily for the presence of arthritis and a clinical score was 
recorded weekly for the IP joints. Swelling of the MCP and MTP joints, tarsal and 
carpal joints, elbows, knees, shoulders, hips and spinal joints were documented but 
not scored on a scale. 
Radiographic examinations 
Radiographic projections were made (with a Kodak X-Omatic cassette, single fine 
screen) of hands, wrists, feet, ankles, knees and elbows. The first projections were 
made as soon as the first clinical signs of arthritis were observed. The follow-up 
projections were made at about 3 weeks intervals. 
Blood parameters 
Every 14 days the following parameters were measured: 
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- hematological parameters: ESR, total leucocytes, differential white blood cell 
counts, erythrocyte count, platelet count, hemoglobin and hematocrit. 
- biochemical parameters: albumin, total protein, urea, alkaline phosphatase, uric 
acid, glucose and transferrin. 
- acute phase reactants: CRP, alpha-l-anti-trypsin, haptoglobin and complement 
component C3. 
- immunologic parameters: levels of total IgG, IgA and IgM. 
Autoimmune parameters 
To detect IgG, IgA and IgM isotypes of rheumatoid factor, specific conjugated anti-
human IgG, IgA and IgM antibodies were used in an ELISA assay. Before use, the 
anti-human conjugates were first tested for cross-reactivity with rhesus monkey 
immunoglobulins. The IgM rheumatoid factor titer was also determined by latex 
agglutination. Human IgG-coated latex particles were purchased from Behringwerke 
AG, Marburg, Germany. Circulating immune complexes were measured with the 
Clq-binding assay (21). 
Humoral antibody response to collagen 
Titration of serum antibody to B-CII (sample used for primary immunization), was 
performed by ELISA. Flexible 96 well assay plates (Falcon 3911, Oxnard, CA) 
were coated overnight at 4 0 C with antigen (25 Hg/ml) 25 μΐ/well. Plates were 
postcoated with 200 μΐ 3% BSA in PBS for 60 min. Serum samples (1:200) were 
added, 20 μΐ/well, and incubated for 2 h at 37 °C. Subsequently, a peroxidase-
conjugated rabbit anti-monkey IgG-H+L chains fraction (Nordic, Tilburg, The 
Netherlands) was added, 20 μΐ/well, at a 1:10,000 dilution and the plates were 
incubated for 2 h at 370C. Substrate (O-phenyl-enediamine, Kodak, Rochester, NY) 
was added and the reaction was stopped by adding 2N H2SO4. The plates were read 
on a Titertek Multiskan Plus Mark II. 
Necropsy and histology 
Rhesus monkey UT was euthanized on day 122 during a period of active clinical 
arthritis, because of the severe state of the disease. The knee and elbow joints were 
opened and the gross lesions were documented. After fixation, the IP-joints of hand 
and feet were separately embedded in paraffin and sections of 3 μπι were stained 
with hematoxylin-phloxine-saffron (HPS). 
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RESULTS 
Clinical observations 
Arthritis induction Rhesus monkeys immunized with MT, S. pyogenes or E. aero-
faciens, did not demonstrate clinical signs of arthritis (Table 1). 
Four of the eight rhesus monkeys (1 female and 3 males), immunized with 
СП did not reveal any clinical signs of arthritis. Four developed a symmetrical 
polyarthritis mainly located in IP-joints of hand and feet (Fig.l). 
Figure 1, Soft tissue swelling and erythema in hands (A) and feet (B) of rhesus monkey M15,30 
days after onset of disease. 
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Table 1 
Incidence of clinical arthritis in rhesus monkeys after intradermal injection of antigens 
monkey sex Mamu-DR antigen primary immunization second immunization 
dose 
(mg/ml) 
10.0 
10.0 
10.0 
10.0 
10.0 
2.5 
2.5 
5.0 
5.0 
5.0 
5.0 
10.0 
10.0 
l.Oa 
1.0a 
3.0a 
3.0a 
3.0a 
3.0a 
3.0a 
3.0a 
adjuví 
ICFA 
ICFA 
ICFA 
ICFA 
ICFA 
ICFA 
ICFA 
ICFA 
ICFA 
CFA 
CFA 
CFA 
CFA 
CFA 
CFA 
CFA 
CFA 
CFA 
CFA 
CFA 
CFA 
arthritis dose 
(mg/ml) 
adjuvant arthritis 
KD 
Ζ 
Мб 
Y 
2813 
IRW 
ITD 
1TM 
1WY 
M 
M 
M 
F 
F 
M 
M 
M 
F 
5/5 
3/3 
8/2 
8/3 
3/3 
-/4 
5/8 
5/3 
1/2 
1UC M 2/1 
ШІ M 2/8 
1XE M 5/2 
1WJ F 5/5 
INR 
IRÒ 
lUY 
M14 
lOX 
M15 
1JT 
1KM 
M 
F 
M 
M 
F 
M 
F 
F 
5/101 
3/3 
1/2 
2/8 
78 
3/8 
3/2 
3/1 
МГ 
МГ 
МГ 
МГ 
МГ 
SP 
SP 
SP 
SP 
EA 
EA 
EA 
EA 
СИ 
СП 
СП 
СП 
СП 
СП 
СП 
СП 
4.0 
4.0 
4.0 
4.0 
ICFA 
ICFA 
ICFA 
ICFA 
3.0a 
3.0a 
3.0a 
3.0b 
3.0a 
3.0b 
3.0b 
3.0b 
-
-
-
ICFA 
-
ICFA 
ICFA 
ICFA 
+ 
(+) 
M = male; F = female; Mamu-DR = serologically defined equivalent of the HLA-DR type of the rhesus monkey; - = DR blank; 
MT = Mycobacterium tuberculosis; SP = Streptococcus pyogenes; EA = Eubactenum aerofaciens; CII = bovine type II collagen; 
ICFA = incomplete Freunds adjuvant; CFA = complete Freunds adjuvant. Kill isolated from the bovine joint; bCII isolated from the nasal spectrum. 
In this limited number of СП immunized animals, no correlation was found 
between the Mamu-DR type and the incidence or severity of the arthritis (Table 1). 
The very first signs of disease in all animals were: decreased mobility, severe apathy 
and poor appetite associated with loss of weight. The most severe inflammatory 
activity was observed during the first 14 days after onset of arthritis (Table 2). 
Table 2 
Clinical arthritis and radiographic scores of the distal interphalangeal (DIP) and proximal 
interpalangeal (PIP) joints of hands and feet 
monkey 
lOX 
M15 
UT 
1KM 
day 
(a.i/a.o) 
28/0 
42/14 
50/22 
64/36 
72/44 
86/58 
92/64 
106/78 
21/0 
28/7 
34/13 
41/20 
55/34 
62/41 
104/0 
111/7 
118/14 
122/18 
41/ 0 
48/ 7 
55/14 
69/28 
77/36 
83/42 
118/77 
125/84 
140/99 
153/112 
160/119 
HNGERS 
DIP 
(CS/RS) 
1/A 
2/A-B 
2-4 
4 
4 
4/C 
4 
4/C 
2/A 
2-3 
2-3 
2-4 
4 
5/D 
1/A 
3 
3 
3/B 
1 
1-2/A 
2 
1-2 
1/A 
1 
1 
1 
1 
1 
1 
PIP 
(CS/RS) 
1/A 
3/A 
2 
1 
1 
1/A 
1 
1/A 
2/A-B 
2-3 
3 
2-3 
2-4 
4/B-D 
1/A-B 
2-3 
2-3 
2/B 
1 
2/A-B 
1-2 
1 
1/A-B 
1 
1 
1 
1 
1 
1 
FEET 
DIP 
(CS/RS) 
2 
2/A 
2-4 
4 
4 
4/A 
4-5 
4/A 
1/A 
1-2 
2 
2 
2-4 
4-5/C-D 
2/A 
3 
3 
3/B 
1/A 
2/A 
2 
2-4 
4/C 
4 
4 
2-4 
2-4 
2-4 
1 
PIP 
(CS/RS) 
3 
3 
2-3 
2 
2-4 
4/A-B 
4 
4/A 
1/A 
1-2 
2 
1-2 
1 
1/B-C 
2/B 
3 
3 
3/B-C 
1-2/A 
2/A 
2 
1 
1/C 
1 
1 
1 
1 
1 
1 
a.i = after immunization; a.o. = after onset of disease; CS = clinical score; RS = radiographic 
score. Clinical score: 1 = normal, 2 = light STS with redness, 3 = severe STS with redness, 4 = 
loss of flexion and extension, 5 = contracture. Radiographic score: A = normal, В = joint space 
narrowing, С = erosion, D = destruction, E = bony ankylosis 
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Clinical arthritis was first palpable as STS of the IP-joints in hands and feet. 
Only monkey 10X showed a clinical arthritis which started with STS of the carpal 
joints 6 days before it was palpable in the IP joints. STS of carpal and tarsal joints 
was only observed 20-30 days after onset of arthritis. Especially STS of the carpal 
joints was correlated with severity of STS of the IP-joints. No clinical signs of 
arthritis were observed in the MCP- and MTP-joints, nor in shoulders or hips in any 
of the monkeys. UT showed, 10 days before its death, also STS of both elbows and 
both knees. M15 and UT developed a strong STS of the metatarsal-tarsus region of 
both feet (Fig. 1). 
Onset I course arthritis The time of onset of the first signs of arthritis after primary 
immunization, as well as the duration of clinical signs varied among animals 
(Fig.2). 
INR <f 
time after immunization (day) 
clinical arthritis in joints 
• booster imm. with 3.0 mg bovine C N (joint) 
** booster imm. with 3.0 mg bovine CI I (nasal septum) in ICFA 
ι H twice a day 0.1 ml buprenorfme 
ι ι loss of weight 
Figure 2. Onset and duration of clinical signs of arthritis in the joints. 
39 
Three monkeys (M 15, lOX and 1KM) developed arthritis within 42 days 
after primary immunization. Only one monkey (UT) showed the first clinical signs 
10 days after the second immunization. Two animals, M15 and 10X showed an 
acute, self-limiting arthritis of respectively 35 and 46 days. The severe STS, 
especially of the DIP of hands and feet, resulted in contracture of these joints after a 
period of about three weeks (Table 2). The course of arthritis was explosive in UT. 
The state of disease and loss of weight (25% in the last week), after 18 days of 
arthritis, was so severe that it was necessary to euthanize the animal. The course of 
disease in monkey 1KM which developed arthritis with a sub-acute character for 
more than 100 days was exceptional. Slight arthritic activity was most prominent in 
the DIP-joints of the feet after a flare-up of inflammation on day 84. This moderate 
arthritis in 1KM did not result in loss of function, except in the DIP joints of the feet 
due to the continual slight inflammmation (Table 2). 
Radiographic findings 
Radiographic manifestations reflecting the inflammatory process were found in all 
arthritic monkeys. Early radiographic manifestations of the inflammatory process 
were STS and narrowing of the interosseus space, most marked in the IP-joints of 
hands and feet (Table 2). For example in rhesus monkey Ml5 (Table 2, Fig.3), after 
a period of about 40 days, the inflammatory activity resulted in marginal erosions of 
the cartilage and ultimately in total destruction of cartilage and of the underlying 
bone structure. Severe STS in M15 and UT of the metatarsal-tarsus region at both 
feet resulted in focal erosions in the tarsus and carpus. 
Figure 3. Radiographic changes in the right hand of rhesus monkey M15, 41 days after onset of 
disease. 
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Erosion of bone of the processus styloideus of the radius was observed in UT and 
1KM. MCP and MTP joints showed no radiographical abnormalities. Only monkey 
Ml5 showed some erosive lesions on day 41 after the onset of arthritis in MCPl of 
the left hand. No abnormalities were found in the radiographs of other joints such as 
knees, elbows, shoulders and hips. 
Macroscopic observations 
Necropsy was only performed on monkey UT 18 days after active arthritis. All 
large diathrodial joints were examined. Both knees and elbow joints showed 
synovial hyperplasia accompanied by a yellowish discoloration of the synovial 
fluid. The synovial hyperplasia was accompanied by strong edema and hyperaemia. 
The articular cartilage in both knees showed small lesions. 
Histology 
Compared to a normal IP-joint of a non-affected rhesus monkey with smooth 
cartilage surface and normal synovial tissue, several abnormalities were seen in 
arthritic IP-joints (Fig.4). 
Figure 4. IP joint of rhesus monkey UT, 18 days after onset of clinical arthritis in the joint (x40). 
The cartilage layer was thinner than normal with an irregular surface. The synovium 
was hyperplastic with neovascularization and infiltration of mononuclear cells and 
an increased number of fibroblasts. There was clear pannus formation with erosion 
of cartilage and subchondral bone. The joint space was widened and contained 
fibrin, necrotic debris and granulocytes. 
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Laboratory findings 
ESR and CRP The presence and degree of inflammation was mainly reflected by 
the ESR and the CRP levels (Fig.5). The highest levels were measured in the period 
just after the onset of arthritis. In IKM the ESR and CRP were persistently slightly 
elevated during the relatively long period of arthritis. 
150 η 
0 10 20 30 40 50 60 70 BO 90 100 110 120 
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Figure 5. ESR and CRP levels in the arthritic monkeys. 
Only the parameters listed below showed values outside the normal range in the 
arthritic monkeys (Table 3). All other parameters (see Materials and Methods) 
remained within the normal ranges (results not shown). 
Hemoglobinlerythrocyteslhematocrit Anemia was present in three monkeys with 
arthritis, except in UT. This anemia was presented by decreased values of 
hemoglobin associated with reduced counts of erythrocytes and hematocrit. 
Lowered values were detected just before or during the period the first clinical 
symptoms of arthritis were observed in the monkeys. 
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Table 3 
Blood parameters measured in the arthritic rhesus monkeys which were associated with 
arthritic activity 
blood parameter 
(normal range)3) 
hemoglobin 
(6.0-9.1 mmol/1) 
hematocrit 
(0.30-0.441/1) 
erythrocytes 
(4.0-6.4Х1012Л) 
thrombocytes 
(192-605 109/1) 
albumin 
(34-46 gA) 
alkaline 
phosphatase 
(64-414 Щ ) 
C3 
(0.8-1.7 g/1) 
leucocytes 
(3.4-14.3X109/1) 
arthritic 
monkey 
10X 
M15 
1KM 
10X 
M15 
1KM 
10X 
M15 
1KM 
10X 
UT 
lOX 
M15 
1KM 
UT 
lOX 
M15 
1KM 
UT 
lOX 
M15 
1KM 
UT 
lOX 
days after 
onset arthritisb) 
-6 
-4 
0 
-4 
-4 
0 
-4 
-4 
0 
0 
14 
0 
7 
0 
-49 
8 
0 
20 
0 
-49 
0 
7 
0 
-49 
7 
-6 
-22 
-48 
-28 
-30 
-48 
-14 
-14 
-34 
-14 
- 14 
-22 
-20 
-14 
-44 
-48 
-77 
--35 
-14 
-48 
-77 
-14 
- 7 
measured 
values 
4.7 -5.6 
4.4 - 5.2 
4.9 -5.8 
0.23 -0.28 
0.23 -0.27 
0.24 - 0.24 
3.6 -3.9 
3.4 -3.8 
3.7 -3.9 
625 -737 
622 
25 - 28 
19 - 19 
29 
27 
28 - 32 
610 -1361 
750 - 791 
433 - 678 
441 - 619 
1.8 - 2.0 
1.8 - 2.0 
1.8 - 2.5 
2.3 
2.0 - 2.1 
18.7 -27.2 
a) as determined for the rhesus monkeys in TNO Primate Center, Rijswijk, The Netherlands 
b) day 0 = first day rhesus monkey showed symptoms of clinical arthritis 
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Leucocytes Leucocytosis was noted in lOX. There was no evidence of septic arthri-
tis, as this animal had no fever and the bacteriological cultures of blood were 
negative. 
Thrombocytes Thrombocytosis was observed in lOX and IJT during the period of 
severe active arthritis. 
Albumin Hypoalbuminemia was noted in all monkeys which developed arthritis. 
The lowest values could be detected during the period of clinical arthritis, and was 
generally not correlated with the severity of arthritis. 
Serum alkaline phosphatase Increased serum alkaline phosphatase levels were 
associated with active arthritis, except in UT. 
C3 
Elevated levels were found in lOX and 1KM during the period of clinical arthritis. 
In Ml 5 levels remained elevated after the period of active arthritis. 
Immunoglobulins In the monkeys which developed arthritis, the total IgG and IgA 
levels were raised after the onset of arthritis (Fig.6). 
Autoimmune parameters Immune complexes were not found and none of the assays 
resulted in detection of rheumatoid factors in the sera of non-arthritic or arthritic 
rhesus monkeys. 
Sub-clinical inflammatory activity 
In the period before the second immunization, i.e. day 49-35 before onset of clinical 
arthritis in IJT, some of the blood parameters showed values which normally were 
associated with clinical arthritis in the other 3 monkeys. In this period UT showed a 
slightly elevated ESR and CRP level (Fig.5), decreased albumin and increased C3 
and alkaline phosphatase levels (Table 3). In addition, an increase of total IgG was 
observed (Fig.6). Because these parameters were normally associated with clinical 
arthritis these findings were indicative for sub-clinical symptoms of inflammation. 
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Figure 6. Levels of total IgA, IgM and IgG in the arthritic rhesus monkeys. 
Humoral antibody response to type II collagen 
All eight monkeys immunized with B-CII developed IgG antibody titers specific for 
this antigen (Fig. 7). No significant differences between arthritic and non-arthritic 
monkeys were observed. 
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Figure 7. The anti-B-CII IgG antibody levels in non-arthritic (A) and arthritic (B) rhesus 
monkeys. 
DISCUSSION 
In contrast to rodent models in which arthritis can be induced in genetically suscep­
tible strains with MT (2) and cell wall fragments of Streptococcus (5) or Eubac-
terium species (6), these antigens did not result in clinical arthritis in rhesus 
monkeys. This failure to induce arthritis may be due to preexisting immunity to 
these bacterial antigens or to the relatively small number of monkeys used in this 
experiment, which therefore may lack the required МНС-immune response gene(s). 
As reported, B-CII proved to be arthritogenic in 50% of the rhesus monkeys. 
CIA in rhesus monkeys in this study is comparable to other studies (18,19) with 
respect to the affected joints. In all studies CIA is most prominent in the IP-joints of 
hands and feet and observed to a lesser extent in the carpal and tarsal joints. Rubin 
et al. (18) reported that only one out of seven male monkeys developed clinical 
signs of arthritis, but that after necropsy all monkeys revealed evidence of articular 
inflammation. Yoo et al. (19) reported clinical signs in all female monkeys. In 
contrast to these two studies, in which several booster immunizations were applied 
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to induce arthritis, in the present study only one immunization induced clinical or 
subclinical arthritis in 50% of the animals (3 females, 1 male). So, CIA in rhesus 
monkeys exhibits a clear variation in susceptibility and severity of the disease. 
Susceptibility or resistance to CIA in monkeys may possible be influenced by sex or 
could be dependent on the immunization protocol. We checked the СП preparation 
by sodium dodecyl sulphate-gel electrophoresis for contamination, but we can not 
exclude contamination of the СП preparation with other cartilage derived collagens 
like type IX and type XI, from which it is shown that they have arthritogenic 
capacities (22). Genetic factors may also play an important role in the susceptibility 
to CIA. Genetic factors seem to control susceptibility to CIA in rats (23) and mice 
(24, 25). In human RA genetic factors, in particular MHC class II genes, have been 
reported to be associated with the disease (26, 27). This association is not absolute, 
indicating that other factors may play a role in the etiology and/or pathogenesis of 
human RA. 
Genetic factors, other than sex, may also play a role in the susceptibility or 
resistence to CIA in rhesus monkeys. The number of animals in this study was too 
small to draw any firm conclusions. 
Although CIA in rhesus monkeys is not self-perpetuating, clear clinical and 
radiographical similarities with human rheumatoid arthritis exist. For example, the 
peripheral diathrodial joints are often inflamed symmetrically. The major radio-
graphically abnormalities due to inflammation, like STS, narrowing of the joint 
space and marginal bony erosions are also observed in human RA (28). The 
histopathology showed synovial cell hyperplasia, neovascularization, mononuclear 
cell infiltration and pannus formation. These synovitis-related features were also 
reported in rodents (12) and in other CIA-nonhuman primates studies (18, 19, 20), 
and resembles human RA (1). 
Several blood parameters were found to be associated with the arthritic 
activity in rhesus monkeys. ESR and CRP proved to be the most relevant ones for 
inflammatory activity. Increased ESR and CRP values have also been found in 
patients with RA (29, 30). Rheumatoid factors and immune complexes were not 
detected in the serum of arthritic monkeys in this study or other rodent models (12). 
Possibly the formation of immune complexes is restricted to the synovial tissue and 
can not be detected in serum. Next to an elevated level of total IgG and total IgA, 
the arthritic monkeys also developed hypoalbuminia. A polyclonal increase of 
gamma globulin serum levels is frequently observed in seropositive RA patients, 
along with a reduction in the concentration of albumin (31). Other observed 
abnormalities include anemia, leucocytosis, thrombocytosis, and elevated alkaline 
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phosphatase levels. Anemia, usually moderate in degree, is seen in RA (1), whereas 
leucocytosis is common in juvenile arthritis and in RA patients with an acute and 
severe disease onset or acute exacerbations (32). Correlations between thrombo­
cytosis and disease activity, anemia and leucocytosis have been noted in RA (33). In 
arthritic monkeys, highest levels of C3 were associated with periods of severe 
clinical arthritis. It is not clear whether C3 must be considered as an acute phase 
protein (a result of inflammatory activity) or that it plays a role in the pathogenesis 
of CIA. Binding of antibodies to the Rh-CII in the articular cartilage may form 
intra-articular immune complexes, and subsequently activate the complement 
cascade (34). C3 levels are usually normal in RA patients, but they are sometimes 
elevated as much as four times the normal mean values (35). 
In accordance with other studies (18, 19), rhesus monkeys developed a IgG 
antibody response against heterologous CII which was not associated with clinical 
arthritis. A possible reason for the non-correspondance between anti-CII IgG 
antibodies and disease-activity can be that other isotypes are involved or because of 
the existence of multiple non-arthritogenic epitopes on the B-CII molecule and a 
small number of arthritogenic ones. Some studies have shown that anti-CII 
antibodies do not precede the clinical onset of human RA (36). However, significant 
levels were found at the first signs of disease, but had disappeared by the time a 
diagnosis of RA was made (37). Both in human RA and CIA in rhesus monkeys 
anti-CII antibodies may be important as a component in the destruction of articular 
cartilage. Next to antibodies, it is known that Τ cells play an important role in the 
pathogenesis of CIA in rodents (38,39) and that CII-specific Τ cell clones persist in 
the synovial membrane of RA patients (40). Preliminary results from this laboratory 
also indicate that Τ cells are involved in the immune response to CIL 
In conclusion the monkey model resembles many features associated with 
active inflammatory stages of human RA. Since in this study only 50% of the rhesus 
monkeys developed arthritis, there may be a genetic factor for susceptibility, as is 
known in the case of human RA. Because the close phylogenetic relationship 
between man and monkey and the similarities of their immune systems, this rhesus 
monkey arthritis model may elucidate relevant information on mechanisms 
contributing to human arthritic diseases. Moreover, immunomodulating therapies, 
for instance pre-testing of MoAb's to cell surface antigens shared by humans and 
rhesus monkeys, can be performed in rhesus monkeys with a larger predictive value 
for clinical results than those tested in rodents. 
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CHAPTER 3 
COLLAGEN INDUCED ARTHRITIS IN AN OUTBRED 
GROUP OF RHESUS MONKEYS COMPRISING 
RESPONDER AND NON-RESPONDER ANIMALS 
Relation between the course of arthritis and 
collagen-specific immunity 
N.P.M. Bakker, M.G.M, van Erck, C.A.D. Botman, 
M. Jonker and L.A. 't Hart 
Arthritis Rheum. 34:616 (1991) 
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SUMMARY 
It is speculated that the autoimmune response to СП is a driving force in the 
pathogenesis of human RA. In this report we describe the relationship between 
induction of collagen arthritis and the CII-specific humoral as well as cellular 
immune response in rhesus monkeys. Ten of fourteen monkeys immunized with B-
CII developed polyarthritis. Susceptible animals showed a Τ cell response to B-CII; 
resistant animals did not. After the primary immunization, the humoral response to 
B-CII, as well as to Rh-CII, was dominated by antibodies of the IgM isotype in the 
susceptible animals and by antibodies of the IgG isotype in the resistant animals. 
Because of the close phylogenetic relationship between rhesus monkey and humans 
these data contribute valuable information about the role of СП-specific immunity 
in the pathogenesis of human RA. 
INTRODUCTION 
The pathogenesis of chronic inflammatory arthritis is unknown. One hypothesis is 
that СП, a major constituent of the joint-cartilage, is involved as auto-antigen in the 
pathogenesis of arthritis. In support of this hypothesis is the finding of СП-specific 
Τ cells and anti-CII antibody producing В cells in the synovial membrane of 
patients with RA (1,2). CII-specific antibodies have also been found in sera of RA 
patients (3). Arthritis that shares a number of clinical, hematologic, serologic, and 
radiographic features with RA in humans (6) can be induced in rhesus monkeys by 
i.d. immunization with B-CII (4-6). This experimental model can provide valuable 
information about human arthritis because of the close phylogenic relationship 
between rhesus monkey and humans (7). Most data concerning CIA have been 
obtained with inbred strains of rodents (8). In these models it has been shown that 
both cellular and humoral immunity play a role in the pathogenesis of this 
experimental disease (9,10). The antibody response to СП is under the control of the 
MHC (11), and CIA cannot be induced in animals with either inherited or 
experimentally impaired Τ cell function (12-14). Direct evidence for the role of Τ 
cells and antibodies has been gained from studies demonstrating that the disease can 
be induced in naive animals by passive transfer of Τ cells (15) or IgG antibodies 
(16) derived from collagen immunized animals. In the present study the 
mechanism(s) leading to CIA were investigated in a group of fourteen randomly 
selected rhesus monkeys, seven males and seven females, that had been immunized 
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with B-CII. The course of the arthritis and the development of humoral and cellular 
immunity to collagen were assessed. Arthritic activity was assessed by several 
laboratory parameters of inflammation, including serum levels of IL-6. The 
proliferative response of PBMC to B-CII was absent in the 4 monkeys that did not 
develop arthritis, low in monkeys that developed arthritis only after the primary 
immunization, and high in monkeys that also developed an arthritis flare upon 
booster immunization. Moreover, a correlation was found between the severity of 
arthritis and the serum concentration of collagen-specific IgM. The relevance of 
these findings for understanding the pathogenesis of CIA are discussed below. 
MATERIALS AND METHODS 
Animals 
The rhesus monkeys (Macaca mulatta) were bom and raised in the ITRI-TNO 
Primate Center, except for monkeys BB25 and BB37 which were bom in the Zoo 
Beekse Bergen, Arnhem, The Netherlands. All monkeys were typed for Mamu-DR 
antigens according to standard serologic techniques (17). The female monkeys were 
3 to 21 years of age, weighed 2.8-5.8 kg. The male monkeys were 4 to 21 years of 
age weighed 3.9-9.3 kg. The animals were examined, weighed and bled under keta-
min anesthesia. Animals experiencing pain were given 0.06 mg Buprenorfine twice 
daily by i.m. injection (Temgesic, Warrick, Amstelveen, The Netherlands). The 
experiments were approved by the TNO ethical committee for animal experiments. 
Throughout the experiments the animals were under veterinary care. 
Collagen 
Native B-CII, isolated from bovine articular cartilage, was a kind gift from dr. J. van 
Kampen, dr. Jan van Breemen Institute, Amsterdam, The Netherlands. Native B-CII 
from the bovine nasal septum and native type II collagen from rhesus monkey nasal 
septum and articular cartilage were isolated as described elsewhere (6). 
Arthritis induction 
The animals were immunized by i.d. (skin of their back) injection of 1 ml of an 1:1 
emulsion of purified B-CII dissolved in 0.1 M HAc and CFA (Difco Lab., Detroit, 
MI). For booster immunizations the B-CII solution was emulsified with ICFA or 
PBS solution (See Figure 2 for doses). 
The severity of arthritis was assessed by the presence of: a) decreased mobi-
53 
lity and apathy with slight STS, b) moderate STS with redness, or c) severe STS 
with redness. Serologic and macroscopic parameters associated with arthritis were 
previously investigated in 8 of the 14 monkeys of the present study, the findings of 
which have been published elsewhere (6). 
Laboratory parameters of inflammation 
The ESR and the serum levels of CRP were determined by standard procedures 
(SSDZ Hospital, Delft, The Netherlands). Serum levels of IL-6 were assessed 
according to the proliferation of the IL-6 dependent murine hybridoma cell line B9 
(19). The recombinant IL-6 used as a standard and the B9 cell line were a kind gift 
from dr. L.A. Aarden (Central Laboratory of the Red Cross Blood Transfusion 
Service, Amsterdam, The Netherlands). 
Mononuclear cell proliferation assay. 
PBMC were isolated from heparinized blood by density gradient centrifugation 
using lymphocyte separation medium (Organon Teknika, Durham, NC). The cells 
from the interphase of the gradient were washed twice with HBSS (Gibco, Paisley, 
UK) and resuspended in culture medium, consisting of HEPES-buffered RPMI-
1640 (Gibco) supplemented with 200 mM L-glutamine, 0.15 % NaHCOs, 200 U/ml 
penicillin, 200 U/ml streptomycin and 20% heat-inactivated pooled nonimmune 
rhesus monkey serum. PBMC were cultured for 6 days in 96 well round-bottom 
plates (Greiner, Labortechnik, Hamburg, Germany) in a humidified atmosphere 
containing 5% CO2 at 37 0 C at a concentration of 5 χ 104 cells per well. Antigen 
and mitogens were added in the optimal concentrations: 34 μg/ml ConA (Phar­
macia, Uppsala, Sweden) and 50 μg/ml B-CII. For dissolution, B-CII in RPMI-
1640 was heated 30 min at 90 0 C. Cell proliferation was measured by the incor­
poration of [3H]thymidine (0.5 μ Ο per well) during the final 8 hours of the culture. 
The results represent the mean cpm of triplicate cultures and are expressed as SI = 
cpm in mitogen or antigen stimulated culture divided by cpm in cultures containing 
medium alone. 
ELISA for collagen-specific antibodies 
High-activated 96 well polyvinyl chloride plates (Titertek; Flow, Ayrshire, UK) 
were coated overnight at 4 0 C with 10 μ§/ιη1 B-CII or Rh-CII in PBS (50 μΐ per 
well). Wells were postcoated by incubation for 60 min at 37 0 C with 1% BSA in 
PBS (100 μΐ/well). Subsequently, different dilutions of (absorbed) rhesus monkey 
sera were added (100 μΐ/well). After thorough washing the binding of IgM and IgG 
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antibodies was detected with alkaline-phosphatase conjugated antibodies directed 
toward human IgM or IgG (1 μg/ml PBS-1% BSA) (Tago, Burlingame, CA). The 
plates were developed using a substrate solution with 0.5 mg p-nitrophenyl 
phosphate (Sigma) per 0.1 ml of glycine-NaOH buffer containing 1 mM MgCb and 
1 mM ZnCte- Light absorbance was read at 405 nm using a Titertek multiscan 
ELISA reader. Control experiments showed that the binding of the respective 
conjugates to human IgM and IgG could be reduced to background levels by 
preincubation with 1% rhesus monkey serum in PBS (data not shown). These 
conjugates are therefore considered to be highly cross-reactive with rhesus monkey 
immunoglobulin isotypes. 
Absorption of anti-CII antibodies 
For absorption studies native B-CII and Rh-CII were immobilized on Affigel-15 
beads (BioRad, Richmond, CA). Briefly, 500 μΐ of thoroughly washed beads were 
mixed with 1 ml of a 10 or 5 mg/ml solution of collagen in 0.1 M H Ac, containing 
0.3 M NaCl to reduce non-specific binding. The mixture was incubated for 60 min 
at room temperature with gentle stirring. After washing once with 0.1 M H Ac and 
twice with PBS, the beads were postcoated for 60 min at room temperature with 1% 
BSA in PBS. Control beads were coated with BSA. To determine whether 
immobilized collagen could still be recognized by serum antibodies the following 
control experiment was done. Affigel beads (250 μΐ) coated with B-CII at 5 mg/ml 
were mixed with 1 ml of different dilutions in PBS/1% BSA of pooled sera from B-
CII immunized rats. After 60 min of incubation at room temperature with gentle 
stirring, the vials were centrifugated. The residual B-CII-specific IgG in the 
supernatant was determined by ELISA using alkaline phosphatase-conjugated goat-
anti-rat IgG (1.25 μg/ml; Sigma). The titer of B-CII-specific IgG in serum from a 
B-CII immunized rat was reduced from 1:12,800 to 1:1,600 by this absorption 
procedure (Fig.l). Thus, immobilized collagen still can be recognized by serum 
antibodies. 
The beads were used to estimate the amount of Rh-CII specific and B-CII 
specific antibodies in the sera of B-CII immunized monkeys. To this end, 150 μΐ of 
rhesus monkey sera diluted 1:1,500 in PBS was preincubated with 100 μΐ Rh-CII or 
B-CII coated beads. After 2 hours of incubation at 37 0 C, the supematants were cen­
trifugated, and the residual Rh-CII specific IgG and IgM antibodies were determined 
by ELISA. 
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Figure 1. Recognition of immobilized СП by IgG from immune rat serum (see Material and 
Methods for details). 
RESULTS 
Induction and course of clinical arthritis 
Nine of the 14 immunized monkeys (5 of 7 females and 4 of 7 males) developed 
symmetric polyarthritis after the first immunization with B-CII. Monkey UT 
developed clinical symptoms only after a booster immunization (Fig. 2). In all 
monkeys with arthritis the clinical activity was mainly located in the IP joints of the 
hands and feet (6), and the most severe inflammation occurred during the first 21 
days after onset of arthritis. Complete remission occurred in all surviving animals. 
The time of onset, the severity and duration of the clinical arthritis varied 
significantly among the animals. Based on the severity of the clinical arthritis, three 
groups were distinguished (Fig. 2). Group I animals (BB25, 2BN, BB37, 1WF and 
UT) had severe disease activity, with arthritic scores of 3, within 14 days of the 
onset of clinical signs, and it was necessary to euthanize the animals. 
Group II animals (1KM, D3, M15,10X and L65) developed a milder form of 
arthritis. Since a flare of clinical arthritis might be induced by a booster immuniza-
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Figure 2. Incidence, time of onset and clinical course of CIA in rhesus monkeys, grouped according to the severity of clinical arthritis. 
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Table 1 
IL-б, ESR, and CRP levels in rhesus monkeys immunized with bovine type II collagen 
group 
I 
IIA 
IIB 
III 
rhesus 
monkey 
BB25 
2BN 
BB37 
1WF 
UT 
1KM 
D3 
M15 
lOX 
L65 
M14 
1UY 
1RO 
INR 
weeks after 
immunization 
1 
3 
1 
3 
1 
3 
1 
3 
1 
17 
1 
7 
1 
5 
1 
5 
1 
4 
1 
5 
1 
6 
-2 
5 
-2 
5 
-2 
5 
clinical 
Arthritis 
+ 
_ 
+ 
. 
+ 
. 
+ 
. 
+ 
_ 
+ 
_ 
+ 
_ 
+ 
_ 
+ 
-
-/+ 
_ 
-
_ 
-
. 
-
_ 
" 
IL-6 
(U/ml) 
122 
320 
85 
233 
44 
492 
56 
197 
57 
213 
28 
150 
<1 
545 
42 
168 
N.D. 
246 
13 
91 
42 
123 
25 
<1 
28 
33 
<1 
<1 
ESR 
(mm/hr) 
1 
43 
2 
20 
1 
53 
1 
34 
1 
9 
1 
43 
2 
58 
1 
27 
2 
120 
1 
5 
2 
2 
1 
3 
3 
2 
2 
2 
CRP 
(mg/ml) 
1 
380 
1 
186 
1 
230 
1 
302 
1 
35 
1 
105 
1 
334 
1 
163 
1 
159 
1 
91 
1 
1 
1 
1 
1 
1 
1 
1 
N.D. = not done 
See Figure 2 for description of groups. 
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Figure 3. Proliferation of PBMC from group Ι, Π and III rhesus monkeys in cultures with B-CII. 
1) W.A.I. = weeks after immunization. See Figure 2 for description of groups. 
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immunization, group II was divided into subgroups IIA (1KM, D3 and Ml5) and 
IIB (L65 and 10X) for further studies. Arthritis could not be induced in group ΠΙ 
animals (M14, 1UY, 1RO and INR). No correlation was found between the 
serologically defined Mamu-DR antigens and the development of arthritis (Fig. 2). 
The inflammation in the rhesus monkeys with CIA was monitored by changes in 
ESR, CRP and IL-6 levels. As shown in Table 1, all these parameters were 
enhanced in group I and II animals. In group ΠΙ, only monkey M14 had an increase 
in the IL-6 level, but the ESR and CRP levels remained at the background level. 
These negative laboratory parameters exclude the presence a subclinical arthritis in 
group III animals, as has been described elsewhere (6) in monkey UT before the 
booster injection. 
Cellular immune response 
The proliferative response of PBMC to B-СП was assessed at various intervals after 
immunization (Fig.3). Because of the poor condition of the group I animals, 
sufficient blood for isolation of PBMC could be taken only once during the arthritis. 
Two animals in this group (2BN and 1WF) showed a significant proliferative 
response during week 4, but in the other three animals, the SI was low. Group ΠΙ 
animals lacked a proliferative response to B-CII, even after specific challenge. 
Animals Ml4 and INR showed only a weak response at 64 weeks, even after 
repeated immunizations. However, all animals in this group showed a normal prolif­
erative response to ConA and to a panel of antigens (data not shown). Cells obtained 
from the three group IIA animals (1KM, D3 and M15) showed a high proliferative 
response to B-CII after the first immunization. This response remained high or was 
further increased after the booster immunizations, which induced a flare of the 
arthritis. 
In contrast, the proliferative response remained low in the two animals of 
group IIB (10X and L65); these animals did not develop a flare of clinical arthritis 
after the booster immunizations. 
Isotype and specificity of collagen-specific antibodies 
Sera from the animals in each group were tested for the presence of antibodies to B-
CII (no sera were available from monkey 2BN). After the primary immunization, B-
CII-specific antibodies in Group I animals were mainly of the IgM isotype, whereas 
those in group ΠΙ animals were almost exclusively IgG (Table 2). 
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Table 2 
Isotype of antibodies to bovine type Π collagen (В-СП) in the sera of rhesus monkeys immunized with В-СП* 
weeks after immunization 
group/ 0-2 3-5 6-8 9-11 12-14 17-19 35 
monkey IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM 
BB25 0.00 0.03 0.15 1.90 0.78 2.17 
I BB37 0.00 0.02 0.78 1.56 
1WF 0.00 0.03 0.40 1.91 0.89 1.38 
1JT 0.11 0.22 0.68 0.10 2.77** 0.45** 
IKM 
IIA D3 
M15 
lOX 
IIB L65 
M14 
lUY 
III 1RO 
INR 
0.00 
0.01 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.04 
0.17 
0.03 
1.60 
0.09 
0.03 
0.00 
0.00 
0.00 
0.31 
0.40 
2.02 
0.36 
0.09 
0.00 
0.00 
0.00 
0.42 
1.30 
1.24 
1.16 
0.85 
0.11 
0.30 
1.07 
2.96 
2.46 
1.66 
1.39 
0.76 
0.97 
0.08 
0.19 
0.08 
0.43 
2.19 
1.74 
1.79 
1.49 
2.21 
0.12 
0.27 
0.96 
2.97 
0.20 
1.64 
0.59 
0.56 
0.98 
0.08 
0.10 
0.07 
0.24 
1.26 
1.03 
1.66** 
0.50 
0.65 
0.26** 
2.84** 
2.55** 
1.05** 
2.33** 
1.14** 
1.22** 
2.99** 
0.70** 
0.85** 
0.27** 
0.20** 
0.17** 
0.11** 
0.16** 
2.50** 1.60** 
2.50** 0.93** 
•Values are optical density units, as determined by enzyme-linked immunosorbent assay. Sera were not available from monkey 2BN (group I). See 
Figure 2 for description of groups. 
** = after booster immunization 
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Figure 4. Isotype of Rh-CII-specific antibodies in absorbed sera from group I, II and III rhesus 
monkeys. See Figure 2 for description of groups. 
B-CII specific antibodies in group II animals were of the IgG, as well as the IgM 
isotype, but IgG antibodies dominated after week 9. High levels of anti-B-CII 
antibodies of the IgM isotype were found at weeks 3-5 after the primary immuni-
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zation in group I monkeys (except UT) and in monkey M15 of group Π, which had 
developed severe clinical arthritis by that time (Fig.2). 
To differentiate Rh-CII-specific antibodies from species non-specific anti­
bodies, absorbing studies were performed on sera obtained at the onset of arthritis 
(except for D3). As shown in Fig. 4, absorption with Rh-CII-coated beads removed 
a considerably higher percentage of IgM antibodies in group I and II sera than with 
В-СП-coated beads. 
The difference was less distinct for the IgG antibodies. In group ΠΙ animals 
there was a more efficient absorption of IgG antibodies with Rh-CII coated beads 
than with B-CII coated beads. The results from this procedure suggest that the 
majority of the Rh-CII-specific antibodies in group I animals were of the IgM 
isotype, while Rh-CII specific antibodies in group III animals were predominantly 
of the IgG isotype. Rh-CII-specific antibodies in group II animals were both of the 
IgM and the IgG isotype. 
DISCUSSION 
It has been suggested by several investigators that auto-immunity to СП may be 
involved in the initiation and/or perpetuation of the inflammatory process in human 
RA (1-3). In the present study, the possible relation between CIA and the humoral 
and cellular immunity to СП in rhesus monkeys was investigated. 
Based on the course of clinical arthritis after a single immunization with B-
CII, three groups could be discerned: a group that developed severe arthritis (group 
I), a group with moderate arthritic symptoms (group II), and a non-arthritic group 
(group III). Three of the four monkeys without arthritis were males. The lower 
incidence of arthritis in male monkeys has also been reported by Terato et al. (20), 
who studied cynomolgous monkeys (Macaca fascicularis), but the group we studied 
is too small to conclude that there is a statistically significant sex-linked sensitivity 
for CIA in rhesus monkeys. 
With respect to the role of cellular immunity in the initiation of CIA, our 
results show a significant difference in Τ cell reactivity to B-CII between the 
arthritic group I and group II animals and the non-arthritic group III animals after 
the first immunization. In group III animals, the proliferative response of Τ cells to 
B-CII was completely negative. B-CII induced Τ cell proliferation was observed in 
cells from arthritic monkeys, but we found no apparent correlation between the level 
of Τ cell reactivity and the severity of arthritis. The Τ cell reactivities to B-CII in 
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group IIB animals, which failed to develop an arthritis flare after booster immuni­
zation, were low compared with those in group IIA animals. It should be noted that 
only the animals of group IIA had showed an arthritis flare upon booster immuni­
zation. These data suggest that CII-reactive Τ cells are involved in the initiation of 
CIA and that the flare of disease activity is correlated with a relatively strong Τ cell 
reactivity to СП. A slight proliferative Τ cell response to B-CII was observed in two 
non-arthritic monkeys (INR and M14) after 60 weeks. This may be an indication of 
a breakdown of the cellular non-responsiveness to B-CII after several booster 
immunizations with the antigen. This also indicates that in these animals, CII-
reactive Τ cells are part of the Τ cell repertoire. Findings from studies of mice 
support the existence of anti-CII Τ cells in the normal Τ cell repertoire (21). 
Clear differences in the isotype distribution of СП-recognizing antibodies 
were found in each group. The severity of arthritis after the triggering immunization 
corresponded with the serum level of B-CII recognizing antibodies of the IgM 
isotype. Holmdahl et al. (22) provided evidence that the isotype of the anti-CII 
antibodies in mice immunized with native СП is governed by class II MHC antigens 
(H-2q). This could also be the case in our outbred population of rhesus monkeys. 
However, no correlation was found between arthritis and the serologically typed 
Mamu-DR antigens. A definitive answer for a possible correlation between MHC 
antigens and CIA in rhesus monkeys requires a more detailed study of the 
MhcMamu system. The Rh-CII-specific antibodies in the group of monkeys with 
severe arthritis (group I) were mainly of the IgM isotype. In contrast, antibodies to 
Rh-Cn in the non-arthritic animals of group III were predominantly IgG, while sera 
of group II animals, with a relatively mild arthritis, contained Rh-CII-specific 
antibodies of the IgM and IgG isotype. These data suggest that Rh-CII-specific IgG 
antibodies are less important for the initiation of clinical arthritis, but that antibodies 
of the IgM isotype may be responsible for the initiation of CIA. Our results on the 
necessity of IgM antibodies for the development of CIA contrast with data from 
rodent studies. Stuart et al. (16) established that a mild form of CIA can be induced 
in naive rats by passive transfer of purified IgG from collagen-immunized rats. 
Holmdahl et al. (21) demonstrated that the МНС-restricted anti-CII response in 
mice is dominated by IgG antibodies. However, the initiation of CIA resembles in a 
number of aspects an immune-complex disease, with the involvement of comple­
ment and neutrophils (23-26). It has been well established that IgM binding of one 
antibody molecule to an epitope on the cartilage can activate the classical pathway 
of the complement cascade and thus trigger inflammation. In contrast, because at 
least a pair of monomelic IgG molecules is nessecary for activation of the classical 
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complement pathway, a high epitope density is required, and such high density 
might not be present on intact cartilage. 
Based on all these data, we propose that the initiation of CIA in rhesus 
monkeys depends on CII-specific Τ cells, possible in concert with CII-specific 
antibodies of the IgM isotype. The different distribution of CII-specific antibody 
isotypes between the monkeys might be governed by different cytokine profiles. 
Because activated anti-CII Τ cells are only observed in the arthritic monkeys, 
particularly during a disease flare, Τ cell derived lymphokines are of interest. In this 
respect, IL-4, IL-6 and interferon-gamma may be important lymphokines. It is 
known that IL-4 plays a role in the immunoglobulin isotype switching (27), and that 
it can inhibit IgM secretion in vitro (28). IL-6, which was found at high levels only 
in the arthritic monkeys, is a cytokine that, in vivo, can induce polyclonal В cell 
activation and autoantibody production (29). Finally, treatment with interferon-
gamma greatly exacerbates CIA in rodents (30) and enhances antigen-specific IgM 
production by activated В cells (28). A second hypothesis for the diversity of 
immune response to СП among the several groups is based on the observation that 
only in animals with a relative high proliferative Τ cell response to B-CII an arthritis 
flare could be induced by booster immunization with B-CII (group IIA). Usually, 
the disease has an acute and limited course, despite the presence of high quantities 
of СП. These results indicate that suppression of the immune response at the level of 
CII-reactive Τ cells may play a role in the induction and/or pathogenesis of CIA in 
rhesus monkeys. This suppressive mechanism might be responsible for the low 
production of arthritogenic IgM antibodies to Rh-CII in the non-arthritic group ΠΙ 
monkeys. In this context, interesting results have been obtained in mice studies 
showing that Τ cells are involved in resistance to CIA (31) or that protection against 
CIA can be accomplished with a CII-specific Τ cell line (32). 
The findings of our present studies might have implications for understanding 
the pathogenesis of human RA. The elucidation of the initiating event in RA is still 
seriously hampered by the fact that the responsible antigen(s) is not known. CII-
specific Τ cells and В cells secreting predominantly CII-specific IgG antibodies 
have been found in the synovium (1,2) and antibodies of the IgM and the IgG 
isotype have been found in plasma (33), of RA patients. It is tempting to speculate, 
based on our data, that IgM antibodies bind to СП in the joint cartilage and, thus, 
form the focus of an inflammatory reaction. As a consequence of the cartilage 
damage, arthritogenic "self epitopes might become available (34), which may be 
recognized by infiltrating autoreactive Τ cells. These are, then, the cells that are 
primarily responsible for the chronic nature of RA. This attractive animal model 
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unifies the contribution of humoral and cellular autoimmunity to collagen in the 
pathogenesis of RA. 
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CHAPTER 4 
INDUCTION OF TYPE II COLLAGEN-SPECIFIC 
ANTIBODY PRODUCTION IN BLOOD LYMPHOCYTE 
CULTURES OF RHESUS MONKEYS (Macaca mulatta) 
WITH COLLAGEN-INDUCED ARTHRITIS USING 
THE IMMOBILIZED NATIVE ANTIGEN 
L.A. 't Hart, C.A.D. Botman and N.P.M. Bakker 
Clin. exp. Immunol. 83: 375 (1991) 
69 
SUMMARY 
PBMC from rhesus monkeys, previously immunized with B-CII to induce arthritis 
were cultured with the same antigen. Because the native protein is poorly soluble in 
culture medium a heating step is often used. The antigen in this form induced 
PBMC proliferation, but epitopes for the induction of antibody production and 
arthritis were lost. To keep the native protein intact it was coated on affigel beads. 
With the immobilized antigen specific antibody production could be induced. 
INTRODUCTION 
RA is often associated with cellular and humoral autoimmunity to СИ (1-4). The 
possible role of the autoimmunity to a major constituent of the joint cartilage, 
however, is only poorly understood. In recent years CIA has been established as an 
animal model to investigate the mechanism(s) by which experimentally induced 
(auto)immunity to СП can lead to arthritis (5). 
We have investigated in rhesus monkeys the different contribution of humoral 
and cellular immunity to СП to the susceptibility to CIA (6). In that study we 
determined the capacity of PBMC from animals immunized with B-CII to 
proliferate and produce antibodies in culture with the same antigen. A complicating 
factor in such studies is that B-CII in its native form is poorly soluble in culture 
medium and therefore gives unreliable results. Many investigators dissolve the 
protein in culture medium by heating briefly (7). However, immunization of rats 
with a heated B-CII solution emulsified in CFA induced cellular but not humoral 
immunity to the native protein (unpublished data, see also 8). Neither did it evoke 
arthritis, indicating that heating destroys B-CII epitopes which are indispensable for 
the induction of arthritis as well as humoral immunity. Similarly, we could 
demonstrate the induction of proliferation, but not antibody production in cultures of 
rhesus monkey PBMC with heated B-CII. 
In the present study we have developed a procedure for the induction of 
specific antibody production in cultures of rhesus monkey PBMC by immobilization 
of the antigen in its native form. 
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MATERIALS AND METHODS 
Animals 
AU rhesus monkeys were bred and raised at the TNO Primate Center in Rijswijk. 
The animals used for this study had been immunized several times with B-Cll (6). 
The isolation of B-CII from bovine nose septum has been described in the same 
report. Blood for serum production or for the isolation of PBMC was obtained from 
immunized monkeys which developed arthritis (susceptible animals: 1KM, M15, 
D3, L65) or which failed to develop any clinical or serologic sign of inflammation 
(resistant animals: IRÒ, M14). 
Isolation and culture of PBMC 
The animals were anesthetized with 0.1 ml/kg of a mixture of 9 volumes ketamine 
(10 mg/ml; Chassot & Cie AG, Bern, Switzerland) and 1 volume vetranquil (10 
mg/ml acepromazine and 5 mg/ml chlorbutanol; Compagnie Rousselot, Paris, 
France). Blood was taken in heparinized (thromboliquine) vacutainers (Becton 
Dickinson, Meylan Cedex, France) and diluted with an equal volume of HBSS 
(Gibco Ltd., Paisley, Scotland). PBMC were isolated by density gradient 
centrifugation on lymphocyte separation medium (Organon Technika Corporation, 
Durham, NC). The cells from the interphase of the gradients (PBMC) were washed 
twice with HBSS. PBMC were cultured in a humidified atmosphere containing 5% 
C02 in 96-well round-bottomed plates (Greiner Labortechnik, Nürtingen, Germany) 
at a concentration of 40,000 cells/well. The culture medium consisted of carbonate-
buffered RPMI 1640 containing 200 mM L-glutamine, 200 U/ml penicillin, 200 
lU/ml streptomycin and 10% (vol.) heat-inactivated fetal calf serum (all from 
Gibco). For stimulation with soluble B-CII the protein was routinely dissolved in 
RPMI 1640 by heating for 30 min at 90°C. Proliferation was assessed by counting 
the number of viable cells in each culture. Results were expressed by the S.I. 
Coating of affigel beads 
Affigel-15 beads (Bio-Rad Laboratories, Richmond, CA) contain N-hydroxy-
succinimide groups which couple to free amino residues in a protein. Usually this 
will not disturb the conformation of the molecule and hence conformational 
epitopes will remain intact. For this study the affigel beads were washed thoroughly 
with 0.05 M HAc. Routinely one volume of the washed beads was mixed with one 
volume of 5 mg B-CII per ml 0.05 M HAc for coating. The mixture also contained 
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0.3 M NaCl to reduce non-specific binding (manufacturer's instruction). When B-
CII concentrations <5 mg/ml were used for coating the beads, the stimulation of 
antibody production was reduced, while beads coated with higher B-CII 
concentrations had only a slightly higher stimulatory capacity (not shown). After 2 h 
incubation at room temperature under gentle stirring the beads were centrifuged. 
After removal of the supernatant the beads were washed at least five times with 
PBS, pH 7.4. For post-coating the whole procedure was repeated with 1% BSA in 
PBS. Beads coated only with BSA functioned as controls in all assays. 
ELISA for Cll-specific antibodies in monkey immune sera 
The assay was performed exactly as described by 't Hart et al. (9). 
Detection of antibody production induced by the beads 
Beads recovered from cell cultures were washed once with PBS and then incubated 
for 1 min with 0.1% Triton X-100 in demineralized water to lyse adherent cells. 
After the beads had been washed throughly with PBS-0.1% Tween 20 (at least five 
times) binding of immunoglobulin was determined by incubation for 1 h at 370C 
with alkaline-phosphatase-conjugated affinity-purified goat antibodies directed to 
heavy chains of human IgM and IgG (Tago, Burlingham, CA). After thorough 
washing with PBS-0.1% Tween 20, the beads were incubated for about 30 min at 
370C with substrate solution. This solution consisted of 0.5 mg p-nitro-phenyl-
phosphate (Sigma Chemical Company, St. Louis, MO) per ml 0.1 M glycine-NaOH 
buffer (pH 10.4), containing 1 mM MgC12 and 1 mM ZnC12. Colour development 
was read at 405 nm. 
RESULTS 
Recognition of native and heated B-CII by monkey immune sera 
Immune-sera from four susceptible B-CII-immunized monkeys at 200-fold dilution 
were pre-incubated with different concentrations of native or heated B-CII. The 
amount of free IgG antibodies to native B-CII after pre-incubation was determined 
with ELISA. As shown in Fig. 1, heating considerably reduced the capacity of B-CU 
to deplete specific IgG from monkey serum. The same experiment was then done 
with immobilized native B-CII. The results in Fig. 2 show that the B-CII-coated 
beads effectively removed specific IgG from rhesus monkey immune sera. Control 
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beads coated with BSA did not remove B-CII-specific IgG. These data show that 
heating of В-СП destroyed epitopes recognized by specific IgG antibodies, but these 
remain intact in the (immobilized) native protein. 
1 0 0
 » S i . - -
heated 
30" cold 
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ΔΑ 10X 
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Figure 1. Destruction of anti-СП IgG antibody epitopes by heating of B-CII. Immune sera were 
incubated with heat-denatured (open symbols) or native (closed symbols) B-CII. After 60 min 
incubation the amount of free IgG antibody to native B-CII was determined with ELISA. Results 
are given as the percentage absorbance (in this ELISA at 405 nm). Results were normalized by 
defining the measured IgG in sera without B-CII at 100%. 
Stimulation of PBMC with soluble B-CII 
In a first experiment the capacity of different concentrations of heated B-CII to 
stimulate proliferation and antibody production in cultures of PBMC was deter­
mined. As shown in Table 1(a) a low but significant proliferation was observed in 
cultures of PBMC from the B-CII-immunized animals 1KM and M15. This prolif­
eration was absent in PBMC from the non-immunized animal Z, or from animal TD 
which had been immunized with an unrelated antigen. No B-CII-specific antibodies 
were detectable with ELISA in any of the cultures. 
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Figure 2. Absorption of antibodies from rhesus monkey serum with B-CII-coated beads. One 
volume of B-CII- (closed symbols) or BSA-coated (open symbols) beads (settled bed volume) was 
incubated at 37°C with 3 volumes of differently diluted immune sera from three monkeys. After 
60 min incubation the amount of free IgG antibodies to B-CII was determined with ELISA. 
Results are given as the percentage absorbance (in this ELISA at 405 nm). The results from the 
different animals were noimalized by defining the measured IgG in sera without B-СП at 100%. 
In a second experiment, PBMC from monkeys 1KM and Ml5 were again stimulated 
with different antigen concentrations. In this experiment recombinant IL2 was 
added as well, aimed at enhancing the production of В cell activation and 
maturation factors by B-CII-activated Τ cells. Despite a strongly increased prolif­
eration (Table lb) in the supematants of these cultures, again no B-CII-specific 
antibodies were detectable with ELISA. 
Stimulation of PBMC with immobilized B-CII 
PBMC from four B-CII-immunized animals were cultured with B-СП-coated beads. 
PBMC were obtained from two susceptible (D3 and 1KM) and two resistant animals 
(1RO and M14). The sera of both groups of animals contain a high amount of B-
Cll-specific IgG. In this experiment the beads of three identical culture wells were 
pooled. The results in Fig. 3 show that B-CII-coated beads induced only PBMC 
from susceptible animals to antibody production, while no antibody production was 
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detectable in cultures with BSA-coated beads. Only antibody molecules binding to 
the beads were found. Antibodies in the culture medium were not detectable. 
This finding was reproduced in three further experiments. Triplicate PBMC 
cultures were stimulated with 25 μΐ settled bed volume of B-CII-coated beads in a 
total culture volume of 150 μΐ. After culture, the beads from each well were 
developed separately. Again the supematants of the cultures did not contain B-CII-
specific antibodies detectable with ELISA, but development of the beads revealed 
binding of В-СП-specific antibodies (Table 2). 
Table 1. 
Stimulation of PBMC with soluble C-II 
(a) Experiment I 
C-II (Kg/ml) 
0 
2.5 
5.0 
10.0 
20.0 
40.0 
(b) Experiment II 
C-II (ЦЕ/ШІ) 
0 
10 
20 
40 
Ζ 
1.0 
1.1 
0.8 
1.1 
0.8 
0.7 
-
1.0 
1.5 
2.1 
1.8 
stimulation index 
TD 
1.0 
1.1 
0.5 
0.5 
0.6 
0.3 
monkey 
rIL2 (U/ 
2 
17.5 
26.5 
32.8 
30.3 
M15 
1.0 
1.4 
1.4 
1.8 
2.6 
3.3 
1KM 
'ml) 
5 
35.5 
42.3 
44.8 
28.0 
1KM 
1.0 
2.3 
2.8 
2.5 
4.3 
6.8 
stimulation index 
10 
38.3 
40.5 
45.0 
41.8 
-
1.0 
1.6 
1.8 
1.8 
monkey M15 
rIL2 (U/ml) 
2 5 
9.6 12.6 
15.4 18.4 
14.8 19.2 
14.8 17.2 
10 
12.8 
18.8 
19.6 
17.0 
PBMC were cultured in triplicate with different doses of В-СП in the absence or presence (only in 
experiment II) of recombinant IL-2 that was added at day 0. After 6 days of culture the number of 
cells per well was counted, and the stimulation index calculated. Donor Ζ was a non-immune 
control monkey; donor TD had been immunized with streptococcal cell walls; donors M15 and 
1KM were monkeys immunized with B-CII which had developed CIA (susceptible animals). 
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Figure 3. Induction of antibody production with B-CII-coated beads. PBMC of four monkeys 
were cultured with different amounts of B-CII- (open symbols) or BSA-coated (closed symbols) 
beads. Monkeys 1KM and D3 were susceptible to CIA induction (a), while 1RO and M14 were 
resistant (b). The beads recovered from triplicate cultures were pooled and developed analogous to 
ELISA plates, as described in Materials and Methods. The results show the light absorbance in 
arbitrary units (OD). 
Table 2 
Stimulation of PBMC with immobilized CH 
coating monkey L65 
BSA-coated beads 98 ±15 
B-CII-coated beads 397 ± 52 
OD (405 nm) 
monkey 1KM 
75 ±12 
215 ±10 
monkey M15 
83 ±1.9 
304 ± 2.3 
PBMC from three CII-immunized susceptible rhesus monkeys were cultured in triplicate for 8 
days with 25 μΐ affigel-15 beads (settled bed) per 150 μΐ culture medium. After culture the binding 
of IgM and IgG was determined. Results are expressed in arbitrary units (OD χ IO3; mean ± S.D.). 
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DISCUSSION 
From a group of 14 rhesus monkeys immunized with B-CII 10 developed CIA. 
These were regarded as susceptible animals. In four animals no CIA could be 
induced, although these have a high titre of B-CII-specific serum antibodies (10). 
The latter animals are therefore regarded as resistant to CIA. Using these two groups 
of animals the role of the immunity raised against СП in the course of CIA has been 
investigated. The results of this study are published separately (6). The present 
report deals with a methodological problem we encountered in that study. 
As also shown in Table 1, PBMC from susceptible animals were induced to 
proliferate in culture with B-CII, although the stimulation remained low. We were 
unable, however, to detect specific antibody production in these cultures even in the 
presence of added IL2. The fact that B-CII is only a weak antigen might, 
particularly, be explained by the fact that B-CII shows a high degree of structural 
homology with autologous СП. Hence, the immunologic response to B-CII might be 
suppressed under the influence of tolerance to self-CII. Addition of IL2 gives a 
strong enhancement of PBMC proliferation. 
Our present results indicate that the heating step, routinely used by many 
investigators to dissolve B-CII in culture medium, destroys epitopes which are 
necessary for recognition by the В cell antigen receptor. Analysis with SDS-PAGE 
showed that the linear alpha-chains of СП remains largely intact (not shown). The 
destroyed determinants are therefore likely conformational epitopes. Because Τ cells 
do not recognize conformational epitopes this will not affect the proliferation of this 
cell type. This explanation is supported by a recent observation in rats that 
immunization with heat-denatured B-CII induced cellular immunity to the native B-
CII, as was tested by delayed type hypersensitivity, but no humoral immunity, as 
measured by serum antibodies. Moreover, animals immunized with the heated 
antigen failed to develop arthritis, indicating also that arthritogenic determinants are 
destroyed. 
It has been demonstrated by Logtenberg et al. (11) that PBMC from patients 
with autoimmune thyroiditis can be induced to produce anti-thyroglobulin 
antibodies in culture with the autoantigen, when it is coated on the surface of affigel 
beads. In the present study we have immobilized B-CII in its native form on affigel 
beads. Our results show that the immobilized native antigen effectively depleted 
antibodies from monkey immune sera, indicating that epitopes recognized by 
antibody molecules remained intact. PBMC from susceptible animals were cultured 
with the B-CII-coated beads or with BSA-coated beads as control antigen. No 
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specific antibodies were found in the culture supernatant, but development of the B-
CH-coated beads revealed attached IgG antibodies. In cultures with BSA-coated 
control beads IgG binding was absent. We conclude therefore that immobilized 
native B-CII induced specific antibody production in PBMC cultures from 
susceptible monkeys. We were unable, however, to induce significant antibody 
production by PBMC obtained from resistant animals. At present, we do not have an 
explanation for this phenomenon. As was shown previously (6) B-CII-induced 
PBMC proliferation was also absent in the animals. An explanation might thus be 
that B-CII-reactive Τ and В cells can be subjected to suppression. The absence of 
antibody production in this resistant group, however, allowed us to conclude that the 
antibodies binding to the B-CII-coated beads are not plasma antibodies that are 
passively transferred with the cells, but are produced in the culture. 
In our view the method described in this paper enables the study of В cell 
immunity to different forms of native CU in rheumatoid arthritic patients at the 
cellular level. 
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INDUCED ARTHRITIS IN RHESUS MONKEYS 
IS REFLECTED BY A Τ CELL 
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SUMMARY 
Ten out of fourteen rhesus monkeys developed arthritis after a single immunization 
with B-CII. In contrast to primary resistant monkeys, arthritic animals showed a B-
CII specific Τ cell proliferation during the induction phase of the diseaes. All 
surviving animals showed a full remission of the disease. Two monkeys acquired 
resistance to CIA after one period of disease, but in three animals a booster 
immunization with B-CII induced a slight flare-up. It is demonstrated that B-CII 
immunized rhesus monkeys have the capacity to restore resistance to CIA. The 
development of resistance to CIA is reflected by a decreased Τ cell responsiveness 
to B-CII. It is shown that the lack of IL2 plays a role in В-СП-induced Τ cell low-
responsiveness. A potential role of CD8+ Τ cells in the down-regulation of the Τ cell 
response to B-CII is discussed. 
INTRODUCTION 
The autoantigen СП might be involved in the pathogenesis of human RA, because 
anti-CII antibodies and Cll-reactive Τ cells are found in serum and joint fluids of 
patients (1-3). A possible causal relation between autoimmunity to СП and arthritis 
is supported by the fact that rodents and monkeys immunized with heterologous or 
autologous СП may develop polyarthritis (4-7). 
Because of the close phylogenetic relationship between rhesus monkeys and man 
(8), the non-human primate arthritis model can provide valuable information on the 
regulation of autoimmunity to CIL As reported earlier, 70% of randomly selected 
rhesus monkeys develop CIA after a single i.d. immunization with B-СП, dividing 
the animals into susceptible and primary resistant animals (9). All susceptible 
animals showed 1 ) a predominance of serum anti-CII antibodies of the IgM isotype 
and 2) a B-CII specific induced proliferation of Τ cells in vitro. On the basis of 
whether a flare-up of arthritis occured following a booster immunization with B-CII, 
the susceptible monkeys were divided into animals with acquired resistance and 
'flare-up' animals (9). Since autoimmunity to СП causes arthritis in the animal 
model, a preexisting or induced suppression of the immune response to СП could 
prevent or abrogate arthritis. The 'flare-up' animals showed a slight disease activity 
during the flare-up, indicating that animals may have developed a decreased 
responsiveness to СП. 
This study has investigated how resistance to CIA is regulated in В-СП-
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immunized rhesus monkeys. Susceptible monkeys seem to acquire resistance to 
CIA, reflected by a decreased in vitro proliferative response of Τ cells to B-CII. 
Both in primary resistant and in susceptible animals the low-proliferative response 
of Τ cells to B-CII could be reversed by exogenous IL2. 
MATERIALS AND METHODS 
Animals 
Rhesus monkeys (Macaca mulatta) were bom and raised in the ITRI-TNO Primate 
Center, except for animals BB25 and BB37 which were bom in the Zoo Beekse 
Bergen, Amhem, The Netherlands. The female monkeys were 3 to 21 years of age, 
weighing 2.8 to 5.8 kg. The male monkeys were 4 to 21 years of age weighing 3.9 
to 9.3 kg. Monkey KD and Ml6 were immunized with MT H37Ra (7). The other 
monkeys received B-CII. All animals were examined, weighed and bled under 
ketamine anesthesia. 
Collagens 
Native B-CII, isolated from bovine articular cartilage, was a kind gift from Dr. J. 
van Kampen, Dr. Jan van Breemen Institute, Amsterdam, The Netherlands. Native 
B-CII from the bovine nasal septum as well as the native СП from rhesus monkey 
nasal septa and articular cartilage (Rh-CII) were isolated as previously described 
(7). 
Arthritis induction 
Animals were immunized with 1.0 ml of an emulsion (1:1) of purified B-CII 
dissolved in 0.1 M HAc and CFA (Difco Lab., Detroit, USA) by i.d. injections in the 
back. For the booster immunizations the B-CII solution was emulsified with ICFA 
or PBS solution. 
B-СП doses in the primary and booster immunizations are given in Fig.l. Disease 
severity was quantified by scoring: 
a) decreased mobility and apathy with slight STS, b) moderate STS with redness, 
c) severe STS with redness. 
Τ cell proliferation assay 
PBMC were isolated, cultured (5 Χ 104 cells/well) for 6 days and assayed for 
antigen specific Τ cell proliferation as described previously (9). Mitogens and 
83 
antigens were applied in the following concentrations; ConA (Pharmacia, Uppsala, 
Sweden) at 33.3 μg/ml and purified protein derivative (PPD) from MT (Statens 
Seruminstitut, Copenhagen, Denmark) at 10 μg/ml. Both B-CII and Rh-CII were 
applied at 50 μg/ml. When indicated, recombinant-human-IL2 (r-IL2)(CIBA-
CEIGY, Switzerland) was added after day 3 of culture in a final concentration of 5 
U/ml, which gave the highest enhancing effect on the CH-induced Τ cell 
proliferation. 
Two-color flow cytometry 
For two-color flow cytometry cultured cells were incubated with fluorochrome-
labelled MoAb: Leu3a/PE (anti-CD4), Leu2a/PE (anti-CD8) and anti-IL2-
receptor/FITC (all Becton Dickinson) or with unconjugated GM 11 (ITRI-TNO) an 
anti-Mamu-DR MoAb in combination with a fluoresceinated goat anti-mouse IgG 
(CLB, Amsterdam, the Netherlands). The cells were incubated for 30 minutes on 
ice. After washing, the cells were analysed with a fluorescence-activated cell sorter 
(FACScan; Becton Dickinson). Lymphocytes were gated on forward and right-angle 
scatter for lymphocyte characteristics to minimize inclusion of other leukocytes in 
the cell count. From each sample, 5,000 cells were analysed. Cells were scored as 
positive or negative staining according to their fluorescence with reference to 
unlabelled control samples. The frequencies of positive cells were expressed as the 
percentage of all PB MC counted. 
RESULTS 
Arthritis induction 
10 out of 14 monkeys developed clinical arthritis after a single immunization with 
B-CII in CFA (9). Five monkeys were euthanized due to the severity of the disease. 
The surviving animals were boosted with B-СП and analysed for exacerbation of the 
disease. As shown in Fig. 1, the monkeys in group A (1KM, D3 and M15) 
developed a flare-up of the clinical arthritis twice after a booster immunization. 
Compared to the disease activity observed during the first flare-up, the activity 
during the second flare-up was lower for animals 1KM and D3. Thus these animals 
seem to acquire resistance to CIA. Animals in group В (10X and L65) developed an 
arthritis after primary immunization, but thereafter showed complete resistance to 
CIA. The group С animals (M14, 1UY, 1RO and INR) never developed any signs 
of clinical arthritis and therefore were regarded as primary resistant. 
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Figure 1. Incidence, onset and course of CIA in group А, В and С rhesus monkeys. G = decreased mobility and apathy with slight STS; ÊJ = 
moderate STS with redness; • = severe STS with redness. Booster immunization is given with an arrow ( * ): A = B-CII (mg) from joint cartilage in 
CFA, В = B-CII (mg) from nasal cartilage in CFA, С = В-СП (mg) from joint cartilage in PBS, D = B-СП (mg) from joint cartilage in ICFA, E = B-CII 
(mg) from nasal cartilage in ICFA. 
oo 
ел 
Table 1 
Highest measured B-CII induced Τ cell proliferation measured in rhesus monkeys (groups А, В and C) at various periods after the primary 
immunization. 
weeks after primary imminization 
0-25 25-50 50-75 75-100 100-125 
group 
A 
В 
С 
monkey 
1KM 
D3 
M15 
10X 
L65 
M14 
1UY 
1RO 
INR 
Ml 
143 
1017 
64 
501 
355 
115 
169 
159 
198 
CII2 
6195*#(43) 
20415 (20) 
3723* (58) 
1726 (5) 
3425 (10) 
138 (1) 
338 (2) 
333 (2) 
285 (1) 
M 
92 
487 
387 
447 
657 
138 
214 
155 
113 
СП 
2944 (32) 
9643 (20) 
3899 (10) 
1622 (4) 
3392 (5) 
265 (2) 
96 (1) 
207 (1) 
265 (2) 
M 
27 
196 
79 
401 
699 
162 
934 
907 
599 
СИ 
22723*#(100) 
3590* (18) 
4734*# (60) 
6191* (15) 
5382* (8) 
1317 (8) 
1328 (1) 
999 (1) 
3186 (5) 
M 
255 
409 
427 
504 
1864 
157 
59 
437 
78 
СП 
3470*#(14) 
3296 (8) 
3239* (8) 
1539 (3) 
1838 (1) 
280 (2) 
702 (12) 
302 (1) 
936 (12) 
M 
274 
1161 
271 
140 
nd3 
56 
301 
nd 
568 
СП 
3017 (11) 
3181 (3) 
1738 (6) 
370* (3) 
nd 
99* (2) 
320* (1) 
nd 
644* (1) 
Numbers represent cpm. Numbers in parentheses represent the SI, which = cpm from cells cultured with CH / cpm from cells cultured only in culture 
medium. 
!) M = culture medium, no antigen 
2) CH = bovine type II collagen, cone: 50ug/ml 
3) nd = not done 
*) Measured within 4 weeks after the booster immunizationwith B-CII in the given period (Fig.l). 
#) Measured during arthritic activity 
oo 
Antigen specific Τ cell proliferation 
As demonstrated before (9), only the arthritic monkeys out of group A and В 
showed after the primary immunization a proliferative Τ cell response to B-CII 
(Table 1). The Τ cell response (reflected in the highest measured Si-value during a 
certain period) is relatively high between week 50 - 75 after the primary 
immunization in two of the three group A monkeys (1KM and M15). During this 
period the animals showed their first flare-up of CIA. After week 75, during the 
second (compared with the first flare-up relatively slight) flare-up activity, these 
animals showed a decreasing Τ cell responsiveness to B-СП. The first flare-up of 
CIA in group A monkey D3 was in the period of week 25 - 50 after the primary 
immunization, after which this animal also showed a decreasing Τ cell response to 
B-CII. This phenomenon was also observed in the monkeys with a complete 
acquired resistance to CIA (group B). The low-responsiveness to B-CII in these 
animals was, compared with the 'flare-up' animals, reached at an earlier stage. This 
indicates a relation between the existance of anti-CII Τ cell activity and the 
possibility to induce a flare-up. After 50 weeks the primary resistant animals out of 
group C, except 1RO, occasionally showed a Τ cell proliferation to B-CII. There 
was no correlation between arthritis activity and the spontaneous (no antigen/ 
mitogen) proliferation of PBMC. 
Proliferation and expression of activation markers on B-CII stimulated Τ 
subsets 
To investigate in the 'flare-up' animals during the period in which they restore 
resistance to CIA which Τ cell subset proliferated to B-СП and to study the level of 
activation of Τ cell subsets between the different groups of monkeys, PBMC were 
isolated in week 70 - 75 after the primary immunization and cultured for 6 days in 
the presence or absence of B-CII. The CD4+/CD8+ ratio's and the expression of the 
activation markers Mamu-DR+ and IL2R on CD4+ and CD8+ Τ cells are shown in 
Table 2. In the 'flare-up' animals (group A) and in monkey L65 (group B) B-CII 
induced a relative increase of CD8+ Τ cells (lower CD^/CDS'·" ratio) and an 
increased expression of both Mamu-DR antigens and IL2R. The same, but to a 
lesser extent, was also observed in the primary resistant monkey INR. Comparing 
both Τ cell subsets, B-CII induced higher percentages of CD8+ Τ cells which 
expressed both activation markers than of CD4+ Τ cells. 
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Table 2 
Percentage of Mamu-DR and IL2R+ cells in PBMC of rhesus monkeys (groups А, В and C) 
after in vitro stimulation with В-СП 
CD4+ CD8+ CD4+ CD8+ 
rhesus CD4/CD8 Mamu-DR+ Mamu-DR+ IL2R+ IL2R+ 
group monkey (%) (%) (%) (%) 
Ml СП2 M СП M СП M СП M СП 
A 
В 
IKM 
D3 
M15 
lOX 
L65 
1.9 
1.1 
1.3 
1.8 
1.1 
0.9 
0.8 
0.9 
1.8 
0.3 
9 
8 
12 
9 
17 
19 
18 
16 
10 
38 
13 
12 
13 
9 
22 
27 
20 
25 
8 
71 
8 
8 
8 
4 
7 
16 
11 
29 
7 
4 
1 
6 
1 
2 
1 
17 
18 
23 
3 
42 
M14 1.8 1.7 9 8 10 9 7 8 2 2 
1UY 1.1 1.3 14 15 15 15 6 5 9 1 
С 
IRÒ 1.3 1.2 6 7 8 7 7 8 3 6 
INR 2.3 1.3 7 9 4 12 7 9 2 9 
!) M = culture medium, no antigen 
2) СП - bovine type II collagen, cone: 50 μg/ml 
The role of IL2 in the proliferative response of Τ cells to B-CII and Rh-CII 
Addition of human r-IL2 after day 3 of culture enhanced the B-CII and the Rh-СП 
induced proliferation of Τ cells in all monkeys, although low in lOX and M14 
(Figure 2). 
To investigate if the effect of r-IL2 was specific for СП, similar experiments were 
done in cultures with PPD. PBMC were used from the B-CII (in CFA) immunized 
monkeys IKM and M15 and from monkeys KD and M6, which had been 
immunized with MT 2.5 years prior to the experiment. The MT immunized animals, 
which were used for control purposes, responded to PPD but not, as expected, to B-
CII (Table 3). Also no effect of IL2 on the culture with B-CII was seen. In contrast, 
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the PPD induced proliferation could be enhanced by exogenous IL2 in the MT 
animals and also in monkey M15. 
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Figure 2. B-CII and Rh-CII induced proliferation of PBMC of rhesus monkeys after the last 
booster immunization with B-CII and the effect of exogenous recombinant IL2. 1, medium; 
2, medium + 112; 3, B-CII (50 Ц§/т1); 4, B-CII + 112; 5, Rh-CII (50 μ^πιΐ); 6, Rh-CII + 112. 
Human recombinant-IL2 was added to the culture on day 4, final concentration 5 U/ml. 
DISCUSSION 
The present study describes the development of resistance to CIA in rhesus 
monkeys. The results demonstrate that 1) rhesus monkeys acquire resistance to CIA 
after one period of arthritis, which was incomplete in the so called 'flare-up' animals, 
2) acquired resistance is reflected by a decreased in vitro Τ cell response to В-СП, 
3) B-CII induces a slight Τ cell proliferation and a preferential activation and 
proliferation of CD8+ Τ cells in the 'flare-up' animals, 4) low-responsiveness of Τ 
cells to B-СП as well as to the autoantigen Rh-СП was reversed by addition of r-IL2 
in all monkeys. 
These findings provide a basis for understanding the role of cellular immunity 
to СП in the course of CIA. For the triggering of the disease after the primary 
immunization are, next to anti-CII IgM antibodies, CII-reactive Τ cells involved (9). 
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The Τ cell low-responsiveness to В-СП was reached at an earlier stage in the 
animals with complete resistance (group B) compared with the 'flare-up' animals. 
Table 3 
Enhancing effect of r-IL2 on the proliferation of PBMC of B-СП and MT immunized rhesus 
monkeys. 
medium 
СопДЗ 
B-CII4 
PPD5 
IL-21 
-/+ 
+ 
+ 
+ 
+ 
B-CII 
1KM 
6172 
3325 
23238 
45214 
4065 
24921 
677 
2801 
monkeys 
M15 
2203 
4044 
56284 
67691 
10309 
31396 
3319 
18196 
MT 
KD 
932 
2714 
36538 
58395 
953 
2271 
5587 
25883 
monkeys 
Мб 
674 
1332 
61939 
73589 
1015 
1178 
8740 
30457 
!) Human recombinant IL2 was added on day 4, final concentration 5 U/ml. 
2) Numbers represent counts per minute. 
3) ConA, concentration: 33.3 μξ/πίί 
4 ) B-СП, concentration: 50 \ig/ml 
5) Tuberculin purified protein derivative, concentration: 10 μ£/πι1 
Because at the time of boosting/flare-up activity the B-CII induced Τ cell 
proliferation in the 'flare-up' animals was relative high and the serum levels of anti-
Cu IgM antibodies were low in all monkeys (data not shown), it is likely that СП 
reactive Τ cells play an important role in the induction of the flare-up activity. 
В-СП induced an activation and proliferation of both CD4+ and CD8+ Τ cells 
in the 'flare-up' animals and in L65 which acquired complete resistance to CIA. 
There is direct evidence from adoptive transfer experiments in rodents that both 
CD4+ and CD8+ Τ lymphocytes can induce resistance to CIA (10-12). A role for 
CD8+ Τ cells in the resistance to CIA in rodents has been suggested in studies in 
which resistance was induced by administration of СП intravenously (13), 
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intraperitoneally (14) or orally (15). It has been described that antigen-specific 
suppressor activity can be mediated in vitro by CD8+ Τ cells (16,17). This may also 
be the case in monkey L65 where a low percentage of CD4+ Τ cells and a high 
percentage of activated CD8+ Τ cells were found after stimulation with В-CU in 
vitro (Table 2). 
Antigen-induced Τ cell proliferation involves both the expression of receptors 
and the secretion of IL2 (18). The fact that addition of (a low-mitogenic 
concentration) IL2 after day 3 of culture enhanced Τ cell proliferation illustrates that 
the low-responsiveness was not due to a reduced capacity to express IL2-R on the 
CII-reactive Τ cells, but that there was a primary lack of IL2 in the culture medium. 
Accordingly, we could not measure IL2 in supematants of СП stimulated PBMC 
(results not shown). 
Low-proliferating (activated) CD8+ Τ cells in the cell cultures (Table 2) may 
be responsible for the lack of IL2 in the supernatant because they strongly absorb 
this lymphokine (19). These observations are in line with data from studies in 
humans demonstrating that antigen-specific unresponsiveness in autoimmune and 
other diseases can be reversed by the addition of exogenous IL2 (20-22). As in 
tuberculosis patients (23), PPD-induced Τ cell proliferation in rhesus monkeys 
could also be enhanced by adding IL2, proving that insufficiency of IL2 in vitro 
plays also a role in Τ cell low-responsiveness to bacterial antigens. It has been 
described in human RA that a defective regulation of the IL2 production may play a 
role in the impaired immunoregulation (24). Our present results show that in normal 
healthy monkeys an experimentally induced autoimmunity to СП is quickly restored 
to normal possibly by the activation of potentially immunosuppressive CD8+ Τ 
cells. Defects found in the suppressor Τ cell compartment of RA patients (25,26) 
might impair this regulatory circuit and therefore facilitate exacerbations. 
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SUMMARY 
CIA is an experimentally inducible autoimmune disorder which is, just like several 
forms of human arthritis, influenced by a genetic background. Immunization of 
young rhesus monkeys (Macaca mulatta) with СП-induced CIA in about 70% of the 
animals. One MHC class I allele was present only in young animals resistant to CIA 
and absent in arthritic animals. This strong association suggests that the MHC class 
I allele itself, or a closely linked gene, determines resistance to CIA. The 
mechanism controlling the resistance to CIA becomes less efficient in aged animals 
since older rhesus monkeys, which were positive for the resistance marker, 
developed a mild form of arthritis. At the cellular level it is demonstrated that 
resistance to CIA is reflected by a low-responsiveness of Τ cells to СИ. This 
association between a specified MHC class I allele and resistance to an autoimmune 
disease points at the importance of the MHC class I region in the regulation of the 
immune response to an autoantigen. 
INTRODUCTION 
The highly polymorphic MHC region, which is known in man as the HLA-system, 
plays a pivotal role in controlling the immune response to foreign pathogens. The 
MHC class I and II glycoproteins bind peptides derived from intracellular enzymatic 
degradation of proteins and subsequently present them on the cell surface to CD8+ 
cytotoxic Τ lymphocytes and CD4+ (primarily helper) Τ cells respectively (1,2). 
MHC class I and II region encoded susceptibility genes for several autoimmune 
diseases have been documented in man and experimental animal models (3-7). 
MHC genes associated with resistance to autoimmune disorders are relative rare and 
have until now only been mapped to the class Π region (8,9). 
CIA is an experimental animal model for studying immunoregulatory 
mechanisms underlying an autoimmune disease. Upon i.d. immunization with СП, 
the major cartilage protein, rhesus monkeys as well as rodents develop CIA which 
shares several pathologic features with human RA (10,11). Human RA is associated 
with the HLA-DR1 and -DR4 serotypes (12,13), while in mice susceptibility to CIA 
has been mapped to a critical site of an I-A allele encoded by the MHC class II 
region (14). 
In this study the genetic influence of MHC genes on the development of CIA 
in rhesus monkeys was investigated. The current knowledge of the MHC of the 
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rhesus monkey, recently named MhcMamu (15), located on chromosome 2, is 
primarily based on serological data. Allo-antisera allow the detection of 13 Mamu-A 
and 14 Mamu-B locus products while more than 10 allelic specificities are encoded 
by the Mamu-DR locus (16,17). Recently the knowledge of the MHC systems in 
different non-human primate species has expanded rapidly. These studies 
demonstrate that MHC polymorphisms are inherited in a trans-species mode of 
evolution (18,19) which means that the evolution of MHC alleles does not start at 
the inception of a species, but is rather a process in which a major group of alleles is 
passed on in the phylogeny from one species to another. The major implication of 
this finding is that some alleles of different species are more related to each other 
than the MHC alleles within a species. This type of relationship may have functional 
implications as is reflected by antigen presentation studies across a species barrier 
(20). Therefore, the identification of MHC genes or alleles as markers for 
susceptibility or resistance to autoimmune disorders in non-human primate models 
may be relevant for understanding the pathogenesis and immunoregulation of 
human autoimmune diseases. 
MATERIAL AND METHODS 
Animals 
Most rhesus monkeys {Macaca mulatta) used in this study were bom and raised at 
the ITRI-TNO Primate Center. Monkeys which were bom outside the Primate 
Center are BB25 and BB37, bom in the Zoo Beekse Bergen, Arnhem, The 
Netherlands; 3974 and 3982, bom in Bethesda Primate Center, USA and monkeys 
2822, 2774 and 3215 were imported from India at a young age. Monkeys 4062, 
4070,4116 and 4106 were imported from Birma at a young age. All monkeys were 
typed for MhcMamu antigens using standard serological techniques (16). The 
animals used in the experiments were randomly selected from the colony. The sex 
and age of the animals are given in Table 1. The animals were examined, weighed 
and bled under ketamin anesthesia. When an animal suffered from pain 0.06 mg 
Buprenorfine was given twice daily by i.m. injection (Temgesic, Warrick BV, The 
Netherlands). The experiments have been approved by the TNO ethical committee 
for animal experiments. Throughout the experiments the animals were under 
veterinary control. 
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Table 1 
Resistance to collagen-induced arthritis in rhesus monkeys is associated with 
Mainu-A26 
rhesus 
monkey 
УОНПЕ 
animals 
BB25 
2BN 
BB37 
1WF 
1JT 
1KM 
D3 
M15 
10X 
L65 
4062 
4116 
4070 
8827 
8765 
8684 
8675 
M14 
1UY 
1RO 
INR 
8769 
8781 
4106 
Qld 
animals 
2774 
3974 
3982 
3215 
2822 
sex 
M 
M 
F 
F 
F 
F 
M 
M 
F 
F 
M 
M 
M 
M 
F 
F 
M 
M 
M 
F 
M 
M 
F 
F 
M 
F 
F 
F 
F 
age* 
(year) 
6.0 
3.5 
3.0 
4.0 
6.5 
6.0 
4.0 
4.0 
5.0 
5.0 
6.0 
7.0 
8.0 
1.5 
3.0 
4.0 
3.0 
4.0 
3.5 
4.5 
5.5 
2.0 
3.0 
6.0 
>23 
>23 
>22 
>23 
>22 
A 
""»" 
11,18 
-.31 
11,32 
11,24 
11,14 
17,18 
11,2 
11,13 
-,2 
11,20 
18,29 
2,31 
2,11 
17,32 
2,17 
2,11 
11,26 
11,26 
24,26 
11,26 
11,26 
2,26 
,26 
11,32 
2,13 
14,32 
13,26 
31,26 
MhcMamu @ 
В 
10,-
9,19 
-,-
9,28 
19,33 
1,19 
3,28 
6,21 
9,9 
"*" 
10,-
33,-
6,-
10,27 
10,27 
10,22 
6,10 
6,19 
19,27 
6,-
21,23 
27,19 
19,23 
6,-
10,19 
6,10 
6,23 
9,6 
33,6 
DR 
3,8 
3,4 
3,2 
2,5 
3,2 
3,1 
1,1 
3,8 
-.8 
2,8 
2,3 
2,4 
2,-
1,2 
101,8 
8,1 
1,3 
2,8 
1,2 
3,3 
5,101 
1,2 
3,3 
8,5 
3,101 
4,1 
4,5 
5,3 
1,3 
immuni­
zation dose* 
(mg) 
1.5 
1.5 
1.5 
1.5 
1.5 
3.0 
1.5 
3.0 
3.0 
1.5 
1.0 
1.0 
1.0 
1.0 
1.0(r) 
1.0(r) 
1.0 
3.0 
3.0 
1.0 
1.0 
1.0 
1.0(r) 
1.0(r) 
1.0 
1.0 
1.0 
1.0 
1.0 
antì-СП** 
T-cell 
response 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
-
-
-
+ 
-
-
+ 
+ 
+ 
+ 
+ 
arthritis*** 
+++ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+(s) 
+(s) 
+(s) 
-
-
-
-
-
-
-
-
++ 
+++ 
+++ 
+(s) 
+ 
Collagens 
Native B-СП, isolated from bovine articular cartilage, was a kind gift from dr. J. van 
Kampen, dr. Jan van Breemen Institute, Amsterdam, The Netherlands. The isolation 
of B-CII and Rh-CII, respectively from the bovine and rhesus monkey nasal septa 
has been described elsewhere (10). 
Arthritis induction 
The animals were immunized by i.d. injection on the back with 1 ml of an emulsion 
(1:1) of purified B-CII or Rh-CII dissolved in 0.1 M H Ac and CFA (Difco Lab., 
Detroit, USA). СИ doses in the primary immunizations are given in Table 1. The 
disease severity was quantified in an arthritic score as explained in the legend of 
Table 1. 
Proliferation of mononuclear cells 
PBMC were isolated from heparinized blood by density gradient centrifugation 
(LSM, Organon, Durham. USA). The cells from the interphase of the gradient were 
washed twice with HBSS (Gibco Ltd., Paisley, Scotland) and resuspended in culture 
medium, consisting of HEPES-buffered RPMI-1640 (Gibco) supplemented with L-
glutamine (200 mM; Gibco), 0.15 % NaHCOa, 200 U/ml penicillin, 200 U/ml 
streptomycin (both Gibco) and 20% heat-inactivated pooled nonimmune rhesus 
monkey serum. PBMC were cultured for 6 days in 96 wells round-bottom plates 
legend Table 1: 
Sex: M = male; F = female. 
$Age at time of immunization. (In captivity rhesus monkeys can reach the maximum of 30-35 
years of age). 
@MhcMamu-A, -B and -DR locus alleles have been identified serologically (16). The A26 allele 
has been printed bold. 
*A11 rhesus monkeys are immunized with B-CII, only the (r) marked animals were immunized 
with Rh-CII. 
**The CII-dependent Τ cell proliferation is scored as negative (-) if the stimulation indices (cpm 
from cells cultured with Cll/cpm from cells cultured only in culture medium) was <2 during the 
first 25 weeks after the primary immunization with CU. A positive score (+) is given when the 
stimulation indices are >2. 
The anti-CII Τ cell response in the responding animals ranged from 1,500 to 23,000 cpm, whereas 
the non-responder animal reached levels of 300 cpm, which is approximately equal to the controls, 
done with medium with no antigen. 
***The arthritic score is as follows: +++ severe STS of all small joints of hands and feet and of 
the wrists and ankle joints, ++ moderate STS of most small joints of hands and feet and wrists and 
ankle joints, + moderate STS only of wrists and ankle joints, +(s) sub-clinical arthritis only 
manifest by elevated ESR and CRP levels and the detection of anti-CII Τ cell response and IgM 
antibodies (30). 
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(Greiner, Labortechnik, Germany) in a humidified atmosphere containing 5% CO2 
at 31°C at a concentration of 5 χ IO4 cells per well. Denatured СП was added in the 
optimal concentration of 50 μg/ml. Cell proliferation was measured by the 
incorporation of [3H]thymidine (0.5 цСі per well) during the final 8 hours of the 
culture. 
RESULTS AND DISCUSSION 
After immunization of 24 MHC typed young animals (<6.5 years of age) with 
heterologous or homologous СП, 16 young animals developed CIA (Table 1). No 
apparent association was observed between susceptibility, sex and immunization 
dose of СП or between Mamu-DR and CIA. However, 7 out of 8 resistant animals 
shared the same serologically defined MHC class I allele (Mamu-A26), which was 
absent in all 18 young animals that developed CIA (P<0.00002). Only one of the 
resistant animals (8675) lacks the Mamu-A26 allele (Table 1). To our knowledge 
this is the first demonstration that resistance to an autoimmune disease, that can be 
evoked by immunization with a soluble antigen, is associated with the MHC class I 
region. Sofar, resistance markers for autoimmune diseases have been exclusively 
linked to the MHC class II region (8,9). The Mamu-A26 associated resistance seems 
unique for CIA since this phenomenon was not observed in rhesus monkeys 
immunized with myelin basic protein to evoke experimental autoimmune ence­
phalomyelitis (data not shown). Because in both models immunization was 
performed with CFA, it is unlikely that the Mamu-A26 associated resistance is due 
to the adjuvant. 
It is generally accepted that during ageing the capacity of the immune system 
to maintain tolerance to autoantigens decreases. To study whether the association 
between Mamu-A26 and resistance to CIA holds true in old animals, 1 male and 4 
female monkeys of more than 22 years of age were immunized with СП. The 
Mamu-A26 positive old animals (3215 and 2822) developed arthritis, but the 
severity of the disease was clearly less than in the Mamu-A26 negative animals 
(Table 1). 
Using biochemical methods the MHC class I gene products were charac­
terized in more detail. One dimensional isoelectrofocussing (ID-IEF) of class I 
products, immunoprecipitated by using the anti-MHC class I monoclonal antibody 
W6/32, demonstrated that the Mamu-A and -B serotypes correlate with isoelectric 
point differences (manuscript in preparation). In addition, such experiments also 
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showed that all Mamu-A26 positive animals share one product with similar 
isoelectric point which was absent in the Mamu-A26 negative animals. 
There appears to exist a strong correlation between the Mamu-A26 allele and 
resistance to develop CIA. The question arises, whether Mamu-A26 itself confers 
resistance, or whether it functions as a marker for a closely linked regulator gene. At 
present it is not known whether the Mamu-A alleles are equivalent to the HLA-A or 
-B alleles. Therefore we can not exclude that other genes, like some of the HLA-B 
associated transcripts (BAT), exhibit polymorphism and may be linked to Mamu-
A26 (21-23). In this respect it is of interest that some BAT genes encode for 
collagen-like structures (24). A potential problem with any association study is 
population stratification. In this case, the A26 allele may mark a subset of rhesus 
monkeys resistant to CIA because of other genes in that subset. In this respect we 
are studying Vb usage in TCR diversity in order to elucidate whether other 
polymorphic gene systems may play a role in resistance to CIA. The alternative 
option is that the Mamu-A26 allele determines resistance by itself. MHC class I 
molecules present peptides from intracellular origin to cytotoxic Τ lymphocytes (1), 
whereas soluble antigens derived from extracellular pathogens are usually presented 
by MHC class II molecules (2). When the Mamu-A26 allele itself is involved in 
resistance to CIA the question has to be answered if Mamu-A26 molecules are able 
to bind self-peptides from СП, which is a soluble antigen. This is not unlikely 
because it has been documented recently that peptides derived from soluble proteins 
can complex with class I molecules (25). As shown in Table 1 resistance to CIA in 
rhesus monkeys is accompanied by in vitro СП-specific Τ cell low-responsiveness. 
The binding of peptides from СП by Mamu-A26 molecules and subsequent 
presentation to regulator CD8 positive Τ cells, which can eliminate antigen 
presenting cells such as СИ reactive В cells and cells of the macrophage lineage 
(26), may be an effective mechanism in the prevention of CIA. After repeated 
immunizations with СП, all arthritic monkeys acquire resistance to the disease, 
which is also reflected by a Τ cell low-responsiveness to СП. Therefore it is possible 
that other class I alleles, although less efficiently than A26, mediate resistance to 
CIA in a similar manner. 
Findings in the human population on associations between certain HLA class 
I alleles and protection to disease are mainly observed for infectious diseases 
(27,28). On the other hand, there exists a strong counterpart of the MHC class I 
linked resistance to CIA in nonhuman primates, namely the association between 
HLA-B27 and AS (3,4), which is an inflammatory disease predominantly affecting 
the joints of the spine and the pelvis. Although MHC class I determines in AS 
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susceptibility and in CIA resistance to disease, both associations are remarkably 
strong. At present it is disputed whether AS is an autoimmune or an infectious 
disease (29). Apart from that the antigen which causes AS has not been identified. 
However, in the case of CIA disease is evoked by a known autoantigen, namely СП. 
Therefore, this arthritis model is most suitable to investigate the role of MHC class I 
genes in the immunoregulation of autoimmune arthritis in primates. 
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CHAPTER 7 
CONCLUDING REMARKS 
After David Trentham in 1977 showed for the first time that rats develop a 
polyarthritis upon immunization with СП, an increasing number of investigators 
have studied СП and its relationship to CIA and human arthritis. 
In this thesis various aspects of CIA in the rhesus monkey are discussed. By 
comparing responder (susceptible) and nonresponder (resistant) animals it was 
possible to associate several clinical and immunologic parameters with the disease. 
В-СП as well as homologous СП proved to be arthritogenic in the rhesus monkey 
(Chapters 2 and 6). It has been shown that, after primary immunization with B-CII 
the activity of CII-reactive Τ cells (monitored by in vitro proliferation to the 
antigen), together with the production of anti-CII IgM antibodies correlates with 
susceptibility to CIA (Chapter 3). Despite high levels of circulating anti-CII IgG 
antibodies resistant monkeys showed no disease symptoms. On the basis of these 
findings it is hypothesized that there is a direct relationship between the activity of 
(certain subtypes of) CII-reactive Τ cells, the subsequent production of В cell 
activating- and differentiating lymphokines, and thus the preferential production of 
anti-CII IgM or IgG antibodies. Anti-СП antibodies, particularly of the IgM isotype, 
are able to trigger the onset of disease by 1) binding to epitopes of self-СП located 
at the surface of intact cartilage in the joint, and 2) subsequently activating the 
complement cascade, resulting in Chemotaxis of leucocytes into the joint. 
The observation that autoimmunity to СП can lead to clinical polyarthritis in the 
rhesus monkey, and that anti-CII antibodies are present in several forms of human 
arthritis, suggests that СП is one of the autoantigens involved in triggering and / or 
perpetuating the autoimmune response in human (chronic) arthritis. This study 
shows that serum levels of anti-CII IgM antibodies in patients should be 
investigated as an early marker of joint inflammation. 
In rhesus monkeys no significant association was found between suscep­
tibility to CIA and certain MHC class II genes. In mice only animals that express the 
MHC class II I-Aq or I-Ar allelic varieties develop CIA. This suggests that in inbred 
mice strains the interaction between a restricted number of СП peptides and MHC 
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molecules is relevant for triggering arthitis. The restricted immune response to СП 
may be due to the inbred character (i.e. homozygotic and less allelic variation) of 
the mice strains used in these studies. Possibly outbred rhesus monkeys develop a 
much more heterogenous immune response to СП, so that an association between 
certain MHC class II genes and susceptibility to CIA is, in comparison to inbred 
rodents, difficult to find. The MHC class II region of the rhesus monkey is currently 
being characterized at the DNA- and at the protein level. This analysis indicates a) 
that there is a high degree of similarity between certain МНС-DR alleles of the 
rhesus monkey and man and b) that class II allelic variation is more diverse than 
assumed earlier on the basis of serological typing techniques. Further analysis of the 
Mamu-class II genes may reveal an association between susceptibility to CIA and 
certain class II genes or MHC haplotypes. 
As well as susceptibility to CIA, this study has focussed on aspects of 
resistance to the disease. Resistant animals produced anti-CII antibodies that were 
predominantly of the IgG isotype after primary immunization with B-CII. This may 
represent a secondary В cell response in the resistant animals (Chapter 2). Given 
that СП is a Τ cell dependent antigen, these data show that resistance to CIA is not 
due to the absence of CII-reactive Τ and В cells. It is more likely that in the resistant 
animals the anti-CII В cells have undergone a triggering prior to immunization, 
potentially mediated by activated CII-reactive Τ cells. The anergic state of the anti-
CII Τ cells (defined by the low in vitro CII-dependent Τ cell proliferation) in the 
resistant animals could be the result of such an activation because it has been shown 
that in susceptible animals, which later acquired resistance to CIA, anti-CII Τ cells 
became anergic after prolonged exposure to the antigen (Chapter 5). An attractive 
explanation for the induction of anergy in vivo, may be that antigen is recognized in 
the absence of costimulatory signals, such as those induced by lymphokines (Nossal 
G., 1989, Science 245:147). Self antigens can be presented by antigen-presenting 
cells which lack the costimulatory activity, such as resting В cells, and the 
interacting Τ cell will become anergic. One aspect of anergy that is of importance 
when discussing pathological autoimmunity is the eventual capability of the anergic 
autoreactive Τ cell to overcome this non-reactive state. This study showed that 
addition of exogenous IL-2 allowed the restoration of the proliferative response of 
anti-СП Τ cells (Chapter 5). Thus, anergic СП-reactive Τ cells are not inert but may 
exert potential effector functions if properly activated. A consequence of the 
reversibility of the anergic state of the autoreactive Τ cells in the presence of IL2 
may be the risk of developing pathological autoimmunity during, for example, 
infection. 
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A mechanism for the active maintenance of anergy would appear to be 
necessary, given that the tolerant state of CII-reactive Τ cells appears to be relatively 
easily reversible. Antigen-specific suppression of the activation of these 
autoreactive Τ cells could be mediated by direct cell-cell contact or by soluble 
factors. By defining the factors involved in suppressing CIA, we may find tools that 
are valuable in the therapy of human arthritis. This study shows that the cellular 
immune response to В-СП is down-regulated and that monkeys can regain their 
tolerance for CIA. The mechanism is unknown, although CD8+ cells may be 
involved in the selective downregulation of anti-CII Τ cell activity (Chapter 5). 
The finding described in Chapter 6, that a certain MHC class I allele is 
associated with resistance to CIA, is unique. Why is it that MHC class I associated 
resistance to an (experimental) autoimmune disease has never been found before? 
There may be several reasons. The lack of such an association in humans may be 
because MHC class I associated resistance only becomes manifest when analysing 
pathological autoimmunity induced by active immunization with СП or other 
autoantigens in CFA, as done in the rhesus monkeys. A second possibility is that 
investigators have always been more focussed on susceptibility markers. For 
example, in RA a lot of work has been performed on the HLA-DR4 variants and 
-DR1 associations which support the concept of a shared epitope as the functional 
unit that forms the molecular basis for disease susceptibility. Further analysis of the 
Mamu-class I locus, i.e. by DNA-sequencing of the different alleles, will possibly 
reveal the existence of a human equivalent of the Mamu-A26 allele. When a human 
homologue of the Mamu-A26 allele is found, epidemiological studies in the human 
population may reveal an (positive or negative) association with arthritis. 
In conclusion, CIA in rhesus monkeys is an unique model in which the 
influence of the MHC on CIA can be studied. Future studies of the role of Mamu-
A26 in resistance to CIA include analysis of the role of antigen-specific Τ cells in 
CIA. In particular, determination of the factors that suppress autoreactive Τ cell 
activity may allow the development of immunization protocols that prevent or 
suppress autoimmune arthritis in humans. 
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SAMENVATTING 
Deze studie met rhesusapen laat zien dat na een eenmalige immunisatie met type Π 
collageen (CII) van rund of rhesusaap (beide geëmulgeerd in compleet Freunds 
adjuvant) in de huid een deel van de dieren een polyartritis ontwikkelden (Hfst. 2 en 
6). Door voor collageen-geïnduceerde artritis (CIA) gevoelige en resistente dieren 
met elkaar te vergelijken was het mogelijk de inductie en verloop van de ziekte te 
associëren met verschillende klinische en immunologische parameters. Zo bleek dat 
alleen bij de gevoelige dieren in vitro een door CII geïnduceerde proliferatie van 
CII-reactieve Τ lymfocyten kon worden gemeten (Hfst. 3). In serum van gevoelige 
dieren konden, naast de aanwezigheid van anti-CII IgG antistoffen, anti-CII 
antistoffen van het IgM type worden gemeten na de eerste immunisatie met CII 
(Hfst. 3). De observatie dat autoimmuniteit tegen CII in de rhesusaap kan leiden tot 
een polyartritis en dat anti-CII antistoffen aanwezig zijn in verschillende vormen 
van humane artritis, suggereert dat CII een van de autoantigenen is betrokken bij het 
ontstaan of onderhouden van de (chronische) gewrichtsontsteking bij de mens. 
Resistente dieren bleken, naast de afwezigheid van een CII afhankelijke Τ cel 
proliferatie, alleen CII-bindende antistoffen van het IgG type te produceren. CII is 
een Τ cel afhankelijk antigeen en dus is het onwaarschijnlijk dat resistentie voor 
CIA in de rhesusaap het resultaat is van de afwezigheid van CII-reactieve Τ cellen. 
De afwezigheid van anti-CII IgM antistoffen, maar de aanwezigheid van anti-CII 
IgG antistoffen, heeft eerder het karakter van een secundaire В cel activiteit (Hfst. 
3). Door de apen meerdere malen te immuniseren met CII bleek dat de voor CIA 
gevoelige dieren een (gedeeltelijke) resistentie tegen de ziekte hadden opgebouwd, 
gepaard gaande met een verlaagd proliferatief vermogen van de CII-reactieve Τ 
cellen (Hfst. 5). 
Verder bleek dat, naast CD4+ Τ cellen, ook CD8+ Τ cellen sterk worden 
geaktiveerd door CII. Dit zou een indicatie kunnen zijn dat CDS"1" Τ cellen 
betrokken zijn bij de selectieve down-regulatie van de anti-CII Τ cel activiteit (Hfst. 
5). De aan- resp. afwezigheid van IL2 speelt in deze geïnduceerde verlaagde Τ cel 
proliferatie ook een rol. Door aanwezigheid van CII en door toevoeging van een 
relatieve lage concentratie IL2 kon in vitro het laag-prolifererende vermogen van de 
CII-reactieve Τ cellen worden opgeheven (Hfst. 5). 
Een opvallend aspect van verschillende humane autoimmuunziekten, zoals bij 
reumatoide artritis (RA) en multiple sclerosis, is dat de gevoeligheid voor deze 
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ziekten geassocieerd blijkt te zijn met de aanwezigheid van bepaalde klasse II 
allelen van het polymorfe zgn. major histocompatibility complex (MHC). Aan­
gezien bekend is dat MHC moleculen een functie hebben bij de presentatie van 
peptiden aan Τ cellen, suggereert deze vinding dat (voor RA en multiple sclerosis 
tot nu toe onbekende) antigenen een rol spelen bij de Pathogenese van de ziekte. 
Omdat in het rhesusaap artritis model het ziekte inducerend antigeen (CII) 
bekend is en alle dieren getypeerd zijn voor hun (op de mens gelijkende) MHC, 
bestond speciale belangstelling voor associaties tussen gevoeligheid voor CIA en de 
aanwezigheid van bepaalde MHC klasse II allelen. Maar in het gebruikte panel apen 
werd geen significante associatie gevonden tussen gevoeligheid voor CIA en de 
aanwezigheid van bepaalde MHC klasse II allelen. Echter, er werd een MHC klasse 
I allei (A26) gevonden, dat geassocieerd bleek te zijn met resistentie voor CIA. 
Verdere studie van het MHC klasse I locus van de rhesusaap, o.a. door bepaling van 
de nuleotide volgorde van het DNA dat codeert voor het A26 eiwit, zal duidelijk 
maken of er een ortholoog allei aanwezig is bij de mens. Indien dit het geval is 
zullen epidemiologische studies moeten uitwijzen of er in de menselijke populatie 
een (positief of negatief) associatie bestaat tussen de aanwezigheid van dit allei en 
bepaalde vormen van artritis. 
Concluderend, CIA in de rhesusaap blijkt een relevant model te zijn om de 
invloed van het MHC op de ziekte te bestuderen. In de nabije toekomst zal de rol 
van het MHC klasse I A26 allei in de resistentie voor CIA nader worden bestudeerd. 
De hypothese is dat er een effectief antigeen-specifiek suppressor mechanisme 
werkzaam is in de A26 positieve dieren dat de ClI-reactieve Τ cellen inactiveert en 
daardoor de aap beschermt voor ziekte. In dit verband zal eerst worden gekeken of 
MHC klasse I moleculen in staat zijn peptiden van CII te binden en te presenteren 
aan Τ cellen. Dit soort onderzoek zal inzicht geven in de factoren die leiden tot 
suppressie cq. regulatie van autoreactieve Τ cellen. Inzichten in het mechanisme 
verantwoordelijk voor resistentie voor CIA in de rhesusaap kunnen van groot belang 
zijn voor ontwikkelingstrategieën die moeten leiden tot een adequate therapie voor 
artritis patiënten. 
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Stellingen behorende bij het proefschrift 
"COLLAGEN-INDUCED ARTHRITIS IN THE RHESUS MONKEY 
Relations between aspects of autoimmunity 
and disease development" 
1 
In de rhesusaap zijn anti-type Π collageen antistoffen van het IgM type belangrijk voor de inductie 
van collageen-artritis. 
Dit proefschrift 
2 
De sterke associatie tussen de aanwezigheid van een MHC klasse I allei en resistentie voor 
collageen-artritis in de rhesusaap duidt op een mogelijke functie van de MHC klasse I regio in de 
immuunrespons tegen type II collageen. 
Dit proefschrift 
3 
Naast MHC klasse Π zijn ook klasse I moleculen in staat oplosbare antigenen aan Τ cellen te 
presenteren. 
E.P. Grant et al, J. Immunol. 148:13 (1992) 
4 
Bij autoimmuunziekten is het begrijpen van de Pathogenese een voorwaarde voor de ontwikkeling 
van effectieve therapieën gebaseerd op immuuninterventie. 
5 
Binnen de immunologie bestaat voor iedere uitzondering een regel. 
6 
Individuen met het humane leukocyten antigeen (HLA)-A26 allei hebben een verhoogd risico om 
een acute graft-versus-host ziekte te ontwikkelen na allogene beenmergtransplantatie. 
D. Weisdorf et ai, Transplantation 51:1197 (1991) 
7 
Geld speelt in de wetenschap geen rol, het bepaalt alleen de richting. 
8 
Niet alle wielrenners hebben het vermogen een berg te beklimmen tijdens het eten. 
Koos Bakker Delft, 27 oktober 1992 



